

1 UNITED STATES DISTRICT COURT
2 FOR THE NORTHERN DISTRICT OF OHIO
3 EASTERN DIVISION

APPLIES TO ALL CASES

6 Hon. Dan A. Polster

9 HIGHLY CONFIDENTIAL

0 SUBJECT TO FURTHER CONFIDENTIALITY REVIEW

Videotaped Deposition of ANUPAM
B. JENA, M.D., Ph.D., held at the offices of
Morgan, Lewis & Bockius, LLP, One Federal
Street, Boston, Massachusetts, commencing at
11:09 a.m., on the 6th of June, 2019, before
Maureen O'Connor Pollard, Registered
Diplomate Reporter, Realtime Systems
Administrator, Certified Shorthand Reporter.

23 GOLKOW LITIGATION SERVICES
877.370.3377 ph | 917.591.5672 fax
deps@golkow.com

Page 2	Page 4
<p>1 APPEARANCES: 2 FOR THE PLAINTIFFS: 3 4 BARON & BUDD, P.C. 5 BY: MARK PIFKO, ESQ. 6 JAY LICHTER, ESQ. (Remotely) 7 15910 Ventura Boulevard, Suite 1600 8 Encino, California 91436 9 818-839-2325 10 mpifko@baronbudd.com 11 jlichter@baronbudd.com 12 13 FOR PURDUE PHARMA: 14 DECHERT LLP 15 BY: MELANIE MACKAY, ESQ. (Remotely) 16 35 West Wacker Drive 17 Chicago, Illinois 60601 18 312-646-5800 19 melanie.mackay@dechert.com 20 21 FOR CARDINAL HEALTH, INC.: 22 WILLIAMS & CONNOLLY LLP 23 BY: MELINDA JOHNSON, ESQ. (Remotely) 24 725 Twelfth Street, N.W. 25 Washington, DC 20005 26 202-434-5452 27 mjohnson@wc.com 28 29 FOR AMERISOURCEBERGEN DRUG CORPORATION: 30 REED SMITH LLP 31 BY: NEIL HLAWATSCH, ESQ. (Remotely) 32 ANNE ROLLINS, ESQ. (Remotely) 33 1717 Arch Street 34 Philadelphia, Pennsylvania 19103 35 215-851-8100 36 nhlawatsch@reedsmitth.com 37 arollins@reedsmitth.com 38</p>	<p>1 APPEARANCES (Continued): 2 FOR JANSSEN and JOHNSON & JOHNSON DEFENDANTS: 3 4 O'MELVENY & MYERS LLP 5 BY: CAMERON BAGHAI, ESQ. (Remotely) 6 610 Newport Center Drive 7 Newport Beach, California 92660 8 213-430-8117 9 cbaghai@omm.com 10 11 FOR HBC SERVICE, INC.: 12 MARCUS & SHAPIRA LLP 13 BY: BENJAMIN KIFT, ESQ. (Remotely) 14 One Oxford Centre, 35th Floor 15 301 Grant Street 16 Pittsburgh, Pennsylvania 15219-6401 17 412-338-4690 18 kift@marcus-shapira.com 19 20 FOR RITE AID: 21 MORGAN, LEWIS & BOCKIUS LLP 22 BY: ELISA P. McENROE, ESQ. 23 JOHN MALOY, ESQ. 24 JOHN P. LAVELLE, JR., ESQ. (Remotely) 25 1701 Market Street 26 Philadelphia, Pennsylvania 19103-2921 27 215-963-5000 28 elisa.mcenroe@morganlewis.com 29 john.maloy@morganlewis.com 30 31 VIDEOPHOTOGRAPHER: Robert Martignetti 32 33</p>
Page 3	Page 5
<p>1 APPEARANCES (Continued): 2 FOR DISCOUNT DRUG MART, INC.: 3 CAVITCH FAMILO & DURKIN, CO., LPA 4 BY: ROBERT WEST, ESQ. (Remotely) 5 1300 E. 9th Street 6 Cleveland, Ohio 44144 7 216-621-7860 8 rwest@cavitch.com 9 10 FOR WALGREENS: 11 BARTLIT BECK LLP 12 BY: LESTER HOUTZ, ESQ. (Remotely) 13 1801 Wewatta Street 14 Denver, Colorado 80202 15 303-592-3197 16 lester.houtz@bartlitbeck.com 17 18 FOR H.D. SMITH: 19 BARNES & THORNBURG LLP 20 BY: ALYSSA HUGHES, ESQ. (Remotely) 21 11 South Meridian Street 22 Indianapolis, Indiana 46204 23 317-261-7881 24 alyssa.hughes@btlaw.com 25 26 FOR WALMART: 27 JONES DAY 28 BY: STEVEN N. GEISE, ESQ. 29 4655 Executive Drive, Suite 1500 30 San Diego, California 92121-3134 31 858-314-1170 32 sngiese@jonesday.com 33</p>	<p>1 INDEX 2 EXAMINATION 3 ANUPAM B. JENA, M.D., Ph.D. PAGE 4 BY MR. PIFKO 9 5 BY MS. MCENROE 177 6 7 E X H I B I T S 8 NO. DESCRIPTION PAGE 9 1 Appendix B to expert report, List of Expert Testimony for Dr. 10 10 Jena..... 65 11 2 Series of timesheets..... 80 12 3 Series of invoices from Analysis 13 13 Group..... 110 14 15 4 May 10, 2019 Expert Report of 11 16 Dr. Anupam B. Jena, MD, PhD..... 131 17 5 Appendix E to expert report, 12 18 falsification analysis of 13 19 Distribution of Opioids and 14 20 Common Non-Controlled Drugs..... 140 21 22 6 Appendix D to expert report, 15 23 Summary of Plaintiff Experts 16 24 Mentioning "Rite Aid"..... 144 25 26 7 Appendix C to expert report, 17 27 Materials Considered..... 154 28 8 Appendix A to expert report, 18 29 Curriculum Vitae..... 166 30 31 9 Analysis Group Affiliate Status 21 32 Report..... 167 33</p>

	Page 6	
1		
2	10 Plaintiffs' Notice of Oral 3 Videotaped Expert Deposition..... 171 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	1 Bockius on behalf of Rite Aid of 2 Maryland, Inc. doing business as 3 Mid-Atlantic Customer Support Center, 4 and here as well defending the 5 witness. I have my colleague John 6 Maloy with me as well. 7 MR. GEISE: Steve Geise from 8 Jones Day on behalf of Walmart. 9 MR. PIFKO: And then people on 10 the phone, if you can say your name, 11 your firm, and who you represent, I 12 would appreciate it. 13 MR. BAGHAI: This is Cameron 14 Baghai from O'Melveny & Myers 15 representing the Johnson & Johnson and 16 Janssen defendants. 17 MR. HLAWATSCH: This is Neil 18 Hlawatsch of Reed Smith for 19 AmerisourceBergen Drug Corporation. 20 MR. WEST: This is Robert West 21 from Cavitch representing Discount 22 Drug Mart. 23 MS. HUGHES: Alyssa Hughes from 24 Barnes & Thornburg on behalf of H.D.
	Page 7	
1	P R O C E E D I N G S	
2		
3	THE VIDEOGRAPHER: We are now 4 on the record. My name is Robert 5 Martignetti. I'm a videographer for 6 Golkow Litigation Services. 7 Today's date is June 6th, 2019, 8 and the time is 11:09 a.m. 9 This video deposition is being 10 held in Boston, Massachusetts, In Re: 11 National Prescription Opiate 12 Litigation. 13 The deponent is Anupam Jena, 14 MD, PhD. 15 The court reporter is Maureen 16 Pollard. 17 Will counsel please identify 18 themselves. 19 MR. PIFKO: Good morning. Mark 20 Pifko from Baron & Budd Los Angeles on 21 behalf of plaintiffs and the executive 22 committee. 23 MS. MCENROE: Good morning. 24 Elisa McEnroe from Morgan, Lewis &	1 Smith. 2 MS. MACKAY: Melanie MacKay 3 from Dechert on behalf of Purdue. 4 MS. JOHNSON: Melinda Johnson 5 of Williams & Connolly on behalf of 6 Cardinal Health. 7 MR. KIFT: Benjamin Kift of 8 Marcus & Shapira on behalf of HBC. 9 THE VIDEOGRAPHER: The court 10 reporter will now swear in the 11 witness. 12 13 ANUPAM B. JENA, M.D., Ph.D., 14 having been duly identified and sworn, was 15 examined and testified as follows: 16 EXAMINATION 17 BY MR. PIFKO: 18 Q. Good morning. My name is Mark 19 Pifko. We just met for the first time off 20 the record a few minutes ago. I'm going to 21 be asking you some questions today, okay? 22 A. Perfect. 23 Q. All right. First thing, can 24 you state and spell your name for the record?

Page 10	Page 12
<p>1 A. Sure. My name is Anupam Jena.</p> <p>2 A-N-U-P-A-M, last name is Jena, J-E-N-A.</p> <p>3 Q. All right. And you've just</p> <p>4 been administered the oath, so you understand</p> <p>5 that your testimony here is under penalty of</p> <p>6 perjury?</p> <p>7 A. Yes, I do.</p> <p>8 Q. Okay. And that means that if</p> <p>9 you lie or are intentionally misleading or</p> <p>10 dishonest, you could be subject to penalties</p> <p>11 from the court.</p> <p>12 Do you understand that?</p> <p>13 MS. MCENROE: Objection to</p> <p>14 form.</p> <p>15 A. I understand that.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Okay. Is there any reason why</p> <p>18 you're not able to provide truthful and</p> <p>19 accurate testimony today?</p> <p>20 A. No, there's no reason.</p> <p>21 Q. Are you taking any medications</p> <p>22 or undergoing any treatment that would impair</p> <p>23 your memory?</p> <p>24 A. No.</p>	<p>1 Q. Three times.</p> <p>2 When was the most recent time</p> <p>3 that you were deposed?</p> <p>4 A. The most recent time I was</p> <p>5 deposed was probably two to three months ago.</p> <p>6 Q. What was that in connection</p> <p>7 with?</p> <p>8 A. That was a litigation matter</p> <p>9 involving two pharmaceutical companies.</p> <p>10 Q. How about the time before that?</p> <p>11 A. The time before that, probably</p> <p>12 four or five months before that.</p> <p>13 Q. So this is in the last -- that</p> <p>14 both of these were in the last year?</p> <p>15 A. That's correct.</p> <p>16 Q. You have three matters listed</p> <p>17 in your appendix. So the first one is the</p> <p>18 antitrust litigation. Is that what -- when</p> <p>19 was the most -- was that the most recent?</p> <p>20 MS. MCENROE: Counsel, are you</p> <p>21 able to give the witness what you're</p> <p>22 looking at so we can all be looking at</p> <p>23 the same page?</p> <p>24 MR. PIFKO: We'll get there.</p>
<p>1 Q. Okay. Is there any reason that</p> <p>2 you can think of why your deposition should</p> <p>3 not proceed today?</p> <p>4 A. No.</p> <p>5 Q. So I'm sure that counsel went</p> <p>6 over the ground rules of the deposition</p> <p>7 before with you so we don't have to waste a</p> <p>8 lot of time doing that, but if you have a</p> <p>9 question, you don't understand something I</p> <p>10 say, please let me know. If not, I'll assume</p> <p>11 that you understand the question. Okay?</p> <p>12 A. Perfect. I'll do that.</p> <p>13 Q. And then just make sure you</p> <p>14 give audible responses because the court</p> <p>15 reporter can't take down shrugs of the</p> <p>16 shoulders and nods of the heads. And then</p> <p>17 don't say uh-huh or uh-uh, because on the</p> <p>18 written record, it looks the same. Okay?</p> <p>19 A. Of course. Thank you.</p> <p>20 Q. So have you been deposed</p> <p>21 before?</p> <p>22 A. I have.</p> <p>23 Q. How many times?</p> <p>24 A. Three times.</p>	<p>1 A. I mean, if you have a copy of</p> <p>2 the report, I can walk through and make sure</p> <p>3 I'm with you.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. You listed three matters that</p> <p>6 you provided prior testimony in --</p> <p>7 A. So the --</p> <p>8 Q. -- that's all I'm asking.</p> <p>9 A. -- the first one</p> <p>10 chronologically is a Lamictal antitrust</p> <p>11 matter.</p> <p>12 The second one, I believe, or</p> <p>13 the third one, is Momenta/Sandoz versus</p> <p>14 Amphastar.</p> <p>15 And the one in between I can't</p> <p>16 recall without looking at the actual sheet.</p> <p>17 Q. And so which was the one that</p> <p>18 you most recently testified in?</p> <p>19 A. The most recent one was the</p> <p>20 Momenta/Sandoz/Amphastar, I believe, but it</p> <p>21 would be --</p> <p>22 Q. Okay.</p> <p>23 A. -- helpful to look at the</p> <p>24 actual.</p>

<p style="text-align: right;">Page 14</p> <p>1 Q. Okay. And then six months or 2 so ago was -- which matter was that? 3 A. I'd have to look at the 4 actual -- 5 Q. Okay. 6 A. -- sheet. I'm involved in many 7 different matters, and so it's hard to keep 8 track of what I've done what and when. 9 Q. Okay. And then you testified a 10 third time as well? 11 A. I've been involved in two 12 depositions and one arbitration. I'm not 13 making a distinguish -- I'm not -- 14 Q. Okay. 15 A. -- distinguishing between those 16 two, but there may be a legal distinction 17 that I'm not aware of. 18 Q. Okay. So you testified twice 19 in a proceeding -- in connection with a 20 proceeding that was pending in a court? 21 A. Correct. 22 Q. And then once in connection 23 with a proceeding that was in an arbitration? 24 A. Correct.</p>	<p style="text-align: right;">Page 16</p> <p>1 MS. MCENROE: Objection to 2 form. 3 A. I have not served any -- as a 4 consulting expert in any other cases. 5 BY MR. PIFKO: 6 Q. You understand that you've 7 provided a report in this matter for Rite 8 Aid, is that correct? 9 A. That is correct. 10 Q. Okay. And you're -- are you 11 providing consulting work for them as well? 12 MS. MCENROE: Objection to 13 form. 14 A. I have been involved in some 15 consulting work prior to the production of my 16 report. 17 BY MR. PIFKO: 18 Q. Okay. And -- but that's in 19 connection with the opioid litigation? 20 A. That is correct. 21 Q. So in the opioid litigation, 22 you're serving as a testifying and a 23 consulting expert for Rite Aid, correct? 24 MS. MCENROE: Objection to</p>
<p style="text-align: right;">Page 15</p> <p>1 And the arbitration one, I'm 2 now jogging my memory, was Ranbaxy 3 Pharmaceuticals, and that was a contract 4 dispute. 5 Q. And when did you provide 6 testimony in connection with that matter? 7 A. Sometime in 2018, I believe. 8 Q. And you've never testified in 9 the history of your life before that? 10 A. Just the three matters that you 11 see there. 12 Q. Okay. Have you served as a 13 testifying expert in any other matters 14 besides those three matters? 15 MS. MCENROE: Objection to 16 form. 17 A. The only three matters that 18 I've served as a testifying expert in are 19 those three that are listed there. 20 BY MR. PIFKO: 21 Q. Okay. Have you served as a 22 consulting expert in connection with any 23 litigation, whether it's pending in a court 24 or arbitration?</p>	<p style="text-align: right;">Page 17</p> <p>1 form. 2 A. In the opioid litigation, I 3 serve as a test -- I'm serving as a 4 testifying expert. All the work that's 5 embodied in my report was the work that I 6 did. 7 There's a separate consulting 8 work that Rite Aid has been doing with a 9 company called Analysis Group that supported 10 my report. I have been peripherally involved 11 in that. But the bulk of my involvement with 12 Rite Aid, the vast majority, in fact, has 13 been related to the report that you have in 14 front of you. 15 BY MR. PIFKO: 16 Q. So other than those three 17 matters, there's no other testifying or 18 consulting work, setting aside the opioid 19 litigation, that you've ever done in your 20 career, is that correct? 21 MS. MCENROE: Objection to 22 form. 23 A. Can you clarify that question? 24 BY MR. PIFKO:</p>

Page 18	Page 20
<p>1 Q. Just, I want to -- I think you 2 already answered, but I want to be crystal 3 clear, that for litigation, whether it be in 4 a court or arbitration, other than those 5 three matters and this matter, you've never 6 served as a consulting or testifying expert, 7 correct?</p> <p>8 MS. MCENROE: Objection to 9 form.</p> <p>10 A. That is correct.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Okay. Have you provided 13 consulting services outside the context of a 14 litigation-type dispute?</p> <p>15 A. I have.</p> <p>16 Q. Okay. When did you first start 17 doing consulting work?</p> <p>18 A. I would say probably 2005, 19 2006, sometime in that time frame.</p> <p>20 Q. I want to talk a little bit 21 about your work history.</p> <p>22 So did you go straight through 23 like high school, college, graduate school? 24 Did you take any breaks?</p>	<p>1 Q. Okay. What year? 2 A. 2000. 3 Q. What was your degree? 4 A. I had two degrees, one in 5 biology and one in economics. 6 Q. Did you attend anywhere 7 in-between high school and MIT, or you went 8 to MIT?</p> <p>9 A. I went straight to MIT. 10 Q. After you finished MIT, where 11 did you go? 12 A. After I finished MIT, I went to 13 University of Chicago.</p> <p>14 Q. Did you get a degree from 15 there? 16 A. I got two degrees from there. 17 I got an MD, which is a medical doctorate, 18 and then a PhD in economics.</p> <p>19 Q. What year was that? 20 A. I started in University of 21 Chicago in June of 2000, I believe, and I 22 left Chicago, University of Chicago, in June 23 of 2009.</p> <p>24 Q. Did you go to any other schools</p>
<p>1 A. I have not taken any breaks. 2 Q. Okay. 3 A. I finished college in, I 4 believe, 19 -- I started college in 1996, 5 went to MIT, finished in 2000, and have been 6 going straight since then. 7 Q. Okay. Let's just quickly go 8 through the degrees and the years that you 9 graduated, and the institutions. 10 So when did you graduate high 11 school? 12 A. 1996. 13 Q. And where did you go to high 14 school? 15 A. I went to a school called the 16 Governor's School for Government and 17 International Studies. It's in Richmond, 18 Virginia. 19 Q. Did you have any sort of 20 specialization there? 21 A. No, just high school. 22 Q. And then you graduated from 23 undergrad from where? 24 A. MIT.</p>	<p>1 after that? 2 A. No. That was the end of my 3 formal education. 4 Q. You didn't do any postgraduate 5 programs or anything like that? 6 A. You mean like a post-doc, is 7 that what you're -- 8 Q. Right. 9 A. -- referring to? 10 So between 2000 -- I'm just 11 going to walk you through the history because 12 it's a little bit complicated. 13 So I started in June of 2000, I 14 took anatomy. In September of 2000, I 15 started in the economics department at the 16 University of Chicago. I did the course work 17 for 2000 to 2002. In that time, I also took 18 medical school courses as well. 19 From 2002 to 2004, I went back 20 to medical school full-time, so two years of 21 medical school, '02 to '04. From '04 to '06, 22 I went back to my PhD in economics, and I 23 completed my dissertation during that period. 24 And I received a PhD from the econ department</p>
Page 19	Page 21

<p style="text-align: right;">Page 22</p> <p>1 in June of 2006, I think.</p> <p>2 From 2006 to 2007, I went to</p> <p>3 UCLA in the RAND Corporation, where, on my</p> <p>4 CV, it -- I'm not sure what it would be</p> <p>5 listed at. I can take a look at it if you</p> <p>6 have a copy for me. But it's a post-doc of</p> <p>7 sorts, because I had just finished my PhD and</p> <p>8 so I was doing some postdoctoral work at UCLA</p> <p>9 in the RAND Corporation. And that was a</p> <p>10 one-year engagement.</p> <p>11 I returned back to University</p> <p>12 of Chicago, I believe, in June of 2007 to</p> <p>13 complete the final two years of medical</p> <p>14 school, and I finished in 2009.</p> <p>15 From 2009 to 2012, I was a</p> <p>16 resident, an intern and resident at</p> <p>17 Massachusetts General Hospital, which is one</p> <p>18 of the Harvard teaching hospitals. It's very</p> <p>19 close to here. During that time, I might</p> <p>20 have been doing some postdoctoral work.</p> <p>21 Again, I don't know what it</p> <p>22 says on the CV, but I was probably doing</p> <p>23 postdoctoral work ongoing with individuals</p> <p>24 from the University of Chicago and from</p>	<p style="text-align: right;">Page 24</p> <p>1 Q. -- where was the first time you</p> <p>2 had a job that you felt like was like a real</p> <p>3 career job that you had?</p> <p>4 MS. MCENROE: Objection to</p> <p>5 form.</p> <p>6 A. The first time I had a job, I'd</p> <p>7 say, would be 2009 when --</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Okay.</p> <p>10 A. -- I entered residency. I</p> <p>11 mean, so I was a graduate student, I was a</p> <p>12 medical student, and it's very common for</p> <p>13 graduate students to do research assistant</p> <p>14 work, and that's what I was doing, I was a</p> <p>15 research assistant.</p> <p>16 I'm calling it consulting</p> <p>17 because the income was not coming from the</p> <p>18 university, whereas a traditional research</p> <p>19 assistant who is supporting a professor might</p> <p>20 get paid from a grant that the university --</p> <p>21 or that the professor has through the</p> <p>22 university, so that's why I'm labeling it as</p> <p>23 consulting. It wouldn't be a job in the way</p> <p>24 that -- it wasn't a full-time job, let's put</p>
<p style="text-align: right;">Page 23</p> <p>1 RAND/UCLA from my time there in the '06-'07</p> <p>2 period.</p> <p>3 Q. Okay.</p> <p>4 A. I hope that clarifies for you.</p> <p>5 Q. No, that's helpful. Thank you.</p> <p>6 A. Perfect. Okay.</p> <p>7 Q. So you said you first served as</p> <p>8 a consultant in 2005-2006?</p> <p>9 A. That would have been the first</p> <p>10 time I did consulting work.</p> <p>11 Q. Okay. What I want to ask you</p> <p>12 is, excluding like summer jobs, mowing lawns,</p> <p>13 or something like -- I'm not sure you did</p> <p>14 anything like that.</p> <p>15 A. I've done that.</p> <p>16 Q. Okay. Was that your first real</p> <p>17 job basically?</p> <p>18 MS. MCENROE: Objection. Form.</p> <p>19 A. That's a vague -- what do you</p> <p>20 mean by "first job"?</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. Well, what I'm trying to get at</p> <p>23 is like --</p> <p>24 A. For --</p>	<p style="text-align: right;">Page 25</p> <p>1 it that way.</p> <p>2 My full-time work from an</p> <p>3 employment perspective began in 2009 when I</p> <p>4 finished res -- when I finished medical</p> <p>5 school and began as an intern at Mass General</p> <p>6 Hospital.</p> <p>7 Q. Okay. So the research</p> <p>8 assistant consulting work that you did, was</p> <p>9 that just a one-off thing, or were there</p> <p>10 several projects that you worked on?</p> <p>11 MS. MCENROE: Objection to</p> <p>12 form.</p> <p>13 A. There was one project in,</p> <p>14 again, I'm saying 2005-2006, I don't know the</p> <p>15 exact date. There was some work that I did</p> <p>16 then probably from 2000 -- let's call it 2006</p> <p>17 until 2012, which is when I finished my</p> <p>18 residency. I had probably several projects</p> <p>19 that I worked on over that six to seven-year</p> <p>20 period.</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. The first project you can</p> <p>23 remember in 2005-2006, who funded that?</p> <p>24 A. The first project was funded by</p>

<p style="text-align: right;">Page 26</p> <p>1 a company called Genentech. 2 Q. What was the nature of that 3 work? 4 A. The nature of that work was an 5 economic evaluation of the war on cancer. I 6 actually can point it to you in my CV. But 7 the basic idea behind the project was that 8 there had been very little investigation as 9 to the changes in survival over time of 10 patients who are affected with cancer in this 11 country, and what I wanted to do was 12 understand, well, how has survival changed 13 for people who have cancer, and what's the 14 economic value of those gains in cancer 15 survival. 16 Q. And then the next consulting 17 job that you did, I'm talking about in this 18 period from 2006 to 2012 that you just 19 described where you're serving as a research 20 assistant type of work, what was the next job 21 after the Genentech work? 22 MS. MCENROE: Objection to 23 form. 24 A. It's hard for me to know. I</p>	<p style="text-align: right;">Page 28</p> <p>1 Genentech, you can't remember any other 2 specific company who funded research that you 3 were working on during 2006 to 2012? 4 MS. MCENROE: Objection to 5 form. 6 A. What I can say is that I 7 suspect that there were other companies that 8 I was working with during that period, I just 9 can't tell you exactly which ones. 10 The reason I remember the 11 Genentech one in particular was, A, because 12 it was my first time doing it, and B, because 13 the work was pretty impactful. The White 14 House office of the report of the president 15 featured the work about the economic value of 16 the war on cancer, the Federal Reserve Bank 17 chair at that time, Ben Bernanke, described 18 the work. So it's left an impression in my 19 memory. Subsequent projects, I think it's 20 hard for me to remember who exactly was 21 involved, but there are probably other 22 companies that I've worked with during that 23 time. 24</p>
<p style="text-align: right;">Page 27</p> <p>1 mean, a lot of the work that I did during 2 that period was related to thinking about the 3 economic value of medical innovations, 4 particularly with respect to cancer care. 5 BY MR. PIFKO: 6 Q. Can you remember any of the 7 other companies who funded projects that you 8 worked on during that 2006 to 2012 time 9 period? 10 MS. MCENROE: Objection to 11 form. 12 A. Not specifically. I mean, I 13 can tell you the companies that I've worked 14 with ever that, you know -- 15 BY MR. PIFKO: 16 Q. We'll get there. 17 A. Yeah. 18 Q. I just want to -- 19 A. Yeah. 20 Q. -- narrow things. 21 A. Yeah. It's hard to pinpoint 22 the time periods exactly. 23 Q. Okay. So sitting here today, 24 there's no other -- you can't -- other than</p>	<p style="text-align: right;">Page 29</p> <p>1 BY MR. PIFKO: 2 Q. Okay. And then from 2009 to 3 2012, you were a resident as well? 4 A. That's correct. 5 Q. Okay. And you earned some 6 income associated with that? 7 A. That's correct. 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>

Page 30	Page 32
[REDACTED]	[REDACTED]

<p>8 BY MR. PIFKO:</p> <p>9 Q. Do you sit on any boards of any 10 companies?</p> <p>11 A. No, I do not.</p> <p>12 Q. Do you own any stock of any 13 pharmaceutical companies?</p> <p>14 A. I only own mutual funds.</p> <p>15 Q. Do you know if your -- you're 16 married, you said?</p> <p>17 A. Yes, sir.</p> <p>18 Q. Do you know if your wife owns 19 any stock in any pharmaceutical companies?</p> <p>20 A. No. She only has the same 21 mutual funds that I do.</p> <p>22 Q. Is she in the medical field as 23 well?</p> <p>24 A. Yes.</p>	<p>1 Q. And then you moved into an 2 academic position at Harvard?</p> <p>3 A. Yes.</p> <p>4 Q. When did you start the Harvard 5 position?</p> <p>6 A. I would say June or July, 2012.</p> <p>7 Q. And then you also maintained a 8 role doing clinical work at the hospital, 9 though --</p> <p>10 A. Yes.</p> <p>11 Q. -- the same hospital where you 12 did your residency?</p> <p>13 A. Exact same hospital, yes.</p> <p>14 Q. And then you started doing some 15 more detailed consulting work?</p> <p>16 MS. MCENROE: Objection to 17 form.</p> <p>18 A. I did the same type of 19 consulting work that I had done prior, and a 20 little -- again, a little bit during, during 21 residency, and I continued doing that kind of 22 work.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. Okay. But you devoted a little</p>
<p>1 Q. What does she do?</p> <p>2 A. She's a musculoskeletal 3 radiologist.</p> <p>4 Q. She just works in the clinical 5 setting?</p> <p>6 A. She actually works about 7 half/half, half clinical/half research. Let 8 me be clear. She works half clinical, 9 one-quarter research, one-quarter quality and 10 safety.</p> <p>11 Q. Where does she work?</p> <p>12 A. She works at Brigham & Women's 13 Hospital.</p> <p>14 Q. And so she just has different 15 roles within the hospital?</p> <p>16 A. That's correct.</p> <p>17 Q. That's in the Boston area?</p> <p>18 A. That's correct.</p> <p>19 Q. Let's talk about the consulting 20 work that you've done from 2012 to 2017, 21 okay?</p> <p>22 So in 2012 you finished your 23 residency, correct?</p> <p>24 A. That's correct.</p>	<p>1 Page 35</p> <p>1 bit more time to that?</p> <p>2 A. I devoted a little bit more 3 time to that, that's correct.</p> <p>4 Q. Thinking back to 2012, what's 5 the first consulting job you can remember?</p> <p>6 A. I can't remember the specific 7 job. I could -- if it's helpful to you, I 8 could talk about the types of projects I do. 9 But in terms of what consulting arrangement 10 or what consulting project I had done in 2012 11 versus 2013 versus 2014, it would be hard for 12 me to parse it out for you.</p> <p>13 Q. Okay. Let's do this then. Can 14 you identify any companies that have hired 15 you to do consulting from 2012 to 2017?</p> <p>16 A. Sure.</p> <p>17 MS. MCENROE: Objection to 18 form.</p> <p>19 A. That's easy to do. I do most 20 of my consulting work through a company 21 called Precision Health Economics, I'll 22 abbreviate it as PHE. And that's the same 23 group that I've been doing work with from 24 2005, 2006. And through that company, I've</p> <p>1 Page 37</p>

<p style="text-align: right;">Page 38</p> <p>1 worked with companies like Amgen, Novartis, 2 Bristol-Myers Squibb, Sanofi, Bluebird, 3 Vertex Pharmaceuticals. That's a range of 4 them.</p> <p>5 A lot of this information that 6 you're actually requesting is publicly 7 available online. Because I'm a physician, 8 there's something called the CMS Open 9 Payments Database, Sunshine Laws, and you can 10 see a lot of these things on there as well.</p> <p>11 Q. Is there any other companies 12 that you can think of who have paid for your 13 work?</p> <p>14 MS. MCENROE: Objection to 15 form.</p> <p>16 A. Can you clarify? What do you 17 mean, paid for my work?</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. Well, what I'm clarifying is 20 I'm guessing you -- do you get a check from 21 Precision Health Economics?</p> <p>22 A. I do receive checks from 23 Precision Health Economics as a consultant.</p> <p>24 Q. Okay. When these companies are</p>	<p style="text-align: right;">Page 40</p> <p>1 right now.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. Okay. So sitting here today, 4 you're not able to remember any other 5 companies? That's what I'm asking you.</p> <p>6 MS. MCENROE: Objection to 7 form.</p> <p>8 A. Let me spend some more time 9 thinking if there's any other companies.</p> <p>10 Years ago I did -- maybe five 11 or six years ago I did work for a company 12 called Hill-Rom. I've done work probably 13 five or six years ago with a company called 14 TESARO, T-E-S-A-R-O. And there may be other 15 companies beyond that.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Okay. But you can't think of 18 any other ones?</p> <p>19 MS. MCENROE: Objection to 20 form.</p> <p>21 A. No. I gave you a list of about 22 ten, I think. That's about as much as I keep 23 in my mind at once.</p> <p>24 BY MR. PIFKO:</p>
<p style="text-align: right;">Page 39</p> <p>1 hiring you, do they pay you directly?</p> <p>2 A. Sometimes they pay me directly.</p> <p>3 Other times it would be through Precision</p> <p>4 Health Economics. And oftentimes the</p> <p>5 consulting work that I do is not company --</p> <p>6 is not company-specific.</p> <p>7 So, for instance, I might work</p> <p>8 with PHE to try and brainstorm research</p> <p>9 ideas, and they may then talk to companies</p> <p>10 about them, but I would never receive a</p> <p>11 payment from them, from the company itself.</p> <p>12 Q. Okay. All I'm trying to ask is</p> <p>13 however the money comes, whether it's</p> <p>14 directly to you or through Precision Health</p> <p>15 Economics, you just listed a bunch of</p> <p>16 companies, are there any other companies you</p> <p>17 can think of who funded your work?</p> <p>18 MS. MCENROE: Objection to 19 form.</p> <p>20 A. There may be other companies,</p> <p>21 not that I can think of. But I would refer</p> <p>22 you to a publicly available database where</p> <p>23 you could sort out that information. But</p> <p>24 those are the companies that come to mind</p>	<p style="text-align: right;">Page 41</p> <p>1 Q. Okay. Have you worked for any 2 other companies like Precision Health 3 Economics?</p> <p>4 MS. MCENROE: Objection. Form.</p> <p>5 A. No. Precision Health Economics</p> <p>6 is the only company that I've done consulting</p> <p>7 work with, what I call health economics</p> <p>8 outcomes research consulting.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. Okay. On this matter, are you</p> <p>11 retained through Analysis Group?</p> <p>12 A. Yes, that's correct.</p> <p>13 Q. Okay. So Analysis Group writes</p> <p>14 you the check?</p> <p>15 A. That's correct.</p> <p>16 Q. Have you done any work through</p> <p>17 any other companies besides Analysis Group</p> <p>18 and Precision Health Economics?</p> <p>19 MS. MCENROE: Objection to 20 form.</p> <p>21 A. No, not besides those.</p> <p>22 As you alluded to earlier, you</p> <p>23 asked earlier have I received any payments</p> <p>24 directly from companies. I have received</p>

<p style="text-align: right;">Page 42</p> <p>1 payments directly from some of those 2 companies that I described. 3 But in terms of either 4 economics consulting work, which is under 5 Precision Health Economics, or litigation 6 consulting work, which is what I've been 7 doing with Analysis Group, no other companies 8 besides those.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. Your litigation work, has that 11 all been through the Analysis Group?</p> <p>12 A. Yes, that has been.</p> <p>13 Q. So as we discussed at the 14 beginning, you're doing some consulting for 15 Rite Aid in the opioid litigation. Setting 16 that aside, have you done any non-testifying 17 work with Analysis Group --</p> <p>18 MS. MCENROE: Objection.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. -- besides the opioid cases?</p> <p>21 A. No. The only work I've done 22 with Analysis Group relates to litigation and 23 expert witness testimony.</p> <p>24 Q. Okay. So the only work that</p>	<p style="text-align: right;">Page 44</p> <p>1 you're the expert. 2 A. I see. 3 No. So I can't comment on the 4 legal term "designated." What I can say is 5 that I'm engaged in other litigation matters 6 that I have been retained as an expert in but 7 I have not filed a report in yet.</p> <p>8 Q. Okay. How many matters is 9 that?</p> <p>10 A. Say five or six.</p> <p>11 Q. When did you start work on 12 those?</p> <p>13 A. Some of the work would have 14 started in 2018. Others I've been retained 15 on in the last month, but I haven't actually 16 done any work for, I've just been retained.</p> <p>17 So when I say five or six, I 18 mean cases I've been retained for, may not 19 have billed any hours to that -- to those 20 cases.</p> <p>21 Q. That's what I was going to get 22 at.</p> <p>23 So of these five or six, how 24 many have you done more than just someone</p>
<p style="text-align: right;">Page 43</p> <p>1 you've done for Analysis Group is the three 2 testifying matters that you listed in your 3 report and the one we're sitting here today 4 in, plus some consulting work for Rite Aid in 5 connection with the opioid litigation, is 6 that correct?</p> <p>7 MS. MCENROE: Objection.</p> <p>8 A. In addition to ongoing matters 9 that I have not -- I have not provided 10 testimony or filed a report in.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Okay. So there are some other 13 matters where you have been retained to 14 potentially be a testifying expert but you 15 haven't been designated?</p> <p>16 MS. MCENROE: Objection to 17 form.</p> <p>18 A. What do you mean by 19 "designated"?</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. Well, formally, when we get 22 your report, or sometimes someone submits a 23 pleading in the case saying here's my expert, 24 then it's known to everybody in the case that</p>	<p style="text-align: right;">Page 45</p> <p>1 called you up and said, "hey, do you want to 2 work on this?" "Okay."</p> <p>3 A. I'd say three, three, four.</p> <p>4 About half to two-thirds of them I've done 5 work, and the other, let's say, quarter I 6 have not done any work yet.</p> <p>7 Q. So of those ones that you have 8 done some work, that started in 2018?</p> <p>9 A. I think that started either 10 late 2017 or early 2018.</p> <p>11 Q. Are those all --</p> <p>12 A. Or just to clarify, my work 13 with Analysis Group started late 2017 or 14 early 2018. The matters that I've 15 been retained in that I haven't filed reports 16 in, I think that the onset of those matters 17 is probably late 2018, because, as I 18 mentioned, some of them I have not been -- 19 done any work in yet. I've just been 20 retained.</p> <p>21 Q. Do you understand the clients 22 who hired you to be confidential?</p> <p>23 A. Can you clarify?</p> <p>24 Q. Those clients where you haven't</p>

<p style="text-align: right;">Page 46</p> <p>1 filed a report, do you understand -- are you 2 allowed to tell me who they are?</p> <p>3 MS. MCENROE: Objection to 4 form.</p> <p>5 A. I'm not aware if I'm allowed to 6 tell you or not. I would suspect that I'm 7 not allowed to tell you.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Okay. During the break, 10 whenever we take a break, I'd like you to 11 look into that and see if you're able to tell 12 me. Okay?</p> <p>13 MS. MCENROE: And we'll talk 14 about it, and then we'll let you know, 15 Mark.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Let's talk about what we can -- 18 whatever we can talk about about those.</p> <p>19 Are those all in the 20 pharmaceutical area?</p> <p>21 A. They are mostly -- they're all 22 in the healthcare area.</p> <p>23 Q. When I say "all of them," I'm 24 talking about all five or six.</p>	<p style="text-align: right;">Page 48</p> <p>1 A. Yes.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. So we talked about 2012 to 2017 4 because we wanted to kind of put aside 5 litigation work, because you weren't doing 6 litigation work in that period, correct?</p> <p>7 A. That's correct.</p> <p>8 Q. So in -- since that time in the 9 late 2017, 20 -- or early 2018 to present, 10 what proportion of your income was derived 11 from litigation-related consulting?</p> <p>12 MS. MCENROE: Objection to 13 form.</p> <p>14 A. I would say probably maybe 15 half, somewhere along that ballpark. So my 16 Harvard income and -- let's call it my pure 17 academic income, which includes research, 18 which includes clinical work, which includes 19 payments I would get for teaching from 20 institutions, academic lectures that I would 21 give at a university, that kind of work 22 probably totals somewhere between [REDACTED] [REDACTED], around that range. And litigation work is somewhere also in that range.</p>
<p style="text-align: right;">Page 47</p> <p>1 A. That's what I'm responding to. 2 Yes.</p> <p>3 Q. Okay. So they're all in the 4 health care field?</p> <p>5 A. Yes.</p> <p>6 Q. Your clients in those, do you 7 know what field of classification they're in?</p> <p>8 MS. MCENROE: Objection to 9 form.</p> <p>10 A. Sure. Yes. So in one or 11 two -- maybe one or two cases, they're 12 biologic drugs to treat cancer. One of the 13 cases is a blood thinner. One of the cases 14 is a diagnostic test. And the other case, I 15 think, involves a few drugs, an antibiotic, 16 possibly a proton pump inhibitor, it's like a 17 reflux medication. None of them have to do 18 with opioids.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. All these matters, you've been 21 retained by a company who is in the business 22 of producing the drug or the product?</p> <p>23 MS. MCENROE: Objection to 24 form.</p>	<p style="text-align: right;">Page 49</p> <p>1 BY MR. PIFKO:</p> <p>2 Q. Have you been paid at any time 3 to be a speaker at a conference or a 4 presentation of any kind?</p> <p>5 A. Can you clarify what you mean 6 by that?</p> <p>7 Q. Well, has any -- okay. Just 8 have you ever been paid to give a lecture?</p> <p>9 A. I have been paid to give 10 lectures, but not been paid by pharmaceutical 11 companies to deliver lectures about their 12 products.</p> <p>13 For instance, I gave a named 14 lecture at the American College of Radiology 15 called the Morton Lecture last year. It's a 16 lecture that's given once a year by the ACR, 17 and they ask a, you know, a speaker to come 18 and give a talk. It's a prestigious thing 19 with 800 to 1,000 people there. So I would 20 have been paid to give that commentary.</p> <p>21 I give grand rounds 22 presentations, so I gave a grand rounds 23 presentation at University of Texas 24 Southwestern. And it's common for an</p>

<p style="text-align: right;">Page 50</p> <p>1 institution to pay a professor to come to 2 give a talk, and it's called an honorarium, 3 and also to pay travel. 4 That's different than -- I have 5 not been paid to talk about the benefits of 6 one drug versus another by a drug company or 7 anything like that. 8 Q. Okay. But I think the thing -- 9 the benefits of a drug or another, that's 10 like a speaker program. Have you ever heard 11 that term before? 12 A. Yes, I've heard that term. 13 Q. So you've never served as a -- 14 in a speaker program for any company? 15 A. Correct. I've never served, 16 and I've never actually been to a speaker 17 program event. 18 Q. Okay. And then you -- when you 19 were just talking about your academic income, 20 you mentioned giving lectures and things, 21 maybe not always at Harvard, maybe at other 22 universities for income. And you said 23 something, I think, that that academic 24 institution pays you for that. Was I -- did</p>	<p style="text-align: right;">Page 52</p> <p>1 form. 2 A. Not that I know of. I mean, I 3 would go meet with -- as -- we talked about 4 me doing consulting work, so I've gone to 5 companies and talked about research, but not 6 in a -- not to, like, talk about a specific 7 drug or anything like that. 8 BY MR. PIFKO: 9 Q. Well, or anything, you know, 10 like presidents get hired to come speak at 11 corporations. 12 A. Oh, I see. No, I have not been 13 hired in the way that Barrack Obama has been 14 hired, no. 15 Q. Okay. 16 A. Yeah. 17 Q. Well, some experts have been 18 paid to come visit some corporation and give 19 a talk about something. 20 A. Yeah. No, no. If you're 21 referring to experts, people getting paid 22 \$20,000 to go give a talk at the retreat of a 23 major company, no, I've not done that before. 24 Q. Okay. How about -- so you</p>
<p style="text-align: right;">Page 51</p> <p>1 I hear you correctly? 2 A. Yes, you did. 3 Q. Okay. So you were just talking 4 about giving some of the grand rounds and 5 some other types of lectures. Was that in 6 the context of where you're getting an 7 academic payment? 8 A. That's an academic, yeah. 9 That's pretty standard across all of 10 academics actually. You know, if an English 11 professor goes to give -- he's at Harvard, 12 goes to give a talk at Brown, they may pay 13 him a \$500 honorarium to come and give a 14 talk. 15 Q. Okay. 16 A. That's exactly what I'm 17 referring to. 18 Q. So then, aside from like a 19 speaker program or these academic programs, 20 have you ever been paid to give, like, a 21 lecture or something anywhere at a conference 22 or like at a -- attend a corporate office and 23 give a speech or anything like that? 24 MS. MCENROE: Objection to</p>	<p style="text-align: right;">Page 53</p> <p>1 all -- you do research as part of your work, 2 correct? 3 A. That's almost all what I do, 4 yeah. 5 Q. Okay. 6 A. I'm a researcher. 7 Q. So when you're doing -- and 8 you've written, I believe your CV says 9 somewhere around the neighborhood of -- 10 you've had around 150 published articles or 11 so. Does that sound right? 12 A. That's correct, about 150 13 scientific articles, so peer-reviewed 14 articles. Probably another 40 to 50 articles 15 that I've authored in the lay press. 16 Q. So the distinction you just 17 made there is the 150 are, like, in academic 18 or medical-type journals? 19 A. That's correct, or economics 20 journals. 21 Q. Okay. 22 A. But academic journals is a good 23 descriptor. 24 Q. Okay. And then the lay press</p>

<p style="text-align: right;">Page 54</p> <p>1 is like if you write an opinion piece in a 2 newspaper, magazine, or something like that? 3 A. Yeah, it could be -- so a lay 4 press is really meaning not peer-reviewed. 5 For instance, if I wrote a 6 piece in the Harvard Business Review, that 7 wouldn't be peer-reviewed by other scholars. 8 And so that's a -- I distinguish that kind of 9 piece from an article of mine in the New 10 England Journal of Medicine. And I've 11 published in Harvard Business Review, 12 Washington Post, New York Times, Wall Street 13 Journal, places like that. 14 Q. Do you receive an income from 15 writing those lay press articles? 16 A. No, I don't receive any income 17 from that. They sometimes -- to be clear, 18 the New York Times, for example, will -- if 19 you write an op ed in the New York Times, I 20 think that they will pay you a couple hundred 21 bucks if you request it. I usually don't 22 because it's a lot of effort to go through 23 their accounts processing system or whatever 24 it's called, so I usually don't do that. But</p>	<p style="text-align: right;">Page 56</p> <p>1 versus -- what's the term where you review a 2 bunch of articles and then write a summary 3 about that? 4 MS. MCENROE: Objection to 5 form. 6 BY MR. PIFKO: 7 Q. So do you do research where you 8 are in a, you know, clinical trial or 9 something where you're collecting original 10 data? 11 MS. MCENROE: Objection to 12 form. 13 A. I do data-driven research, not 14 in a clinical trial setting. I analyze data. 15 It's called observational data. So I use 16 Medicare claims data, insurance claims data, 17 other publicly available databases, and I 18 answer questions based on that data. I've 19 never conducted a randomized controlled 20 trial. 21 BY MR. PIFKO: 22 Q. When you do the research 23 projects, are they funded by outside funding? 24 MS. MCENROE: Objection. Form.</p>
<p style="text-align: right;">Page 55</p> <p>1 that offer is there, and it varies across 2 outlets. HBR, Harvard Business Review, for 3 example, doesn't pay. I know that. 4 Q. Okay. So things like the New 5 York Times thing, it's just not worth the 6 complication of what you have to jump through 7 to get the money? 8 MS. MCENROE: Objection to 9 form. 10 A. Well, I don't know what -- not 11 worth it. \$200 is \$200. That's a -- it's -- 12 I've tried to do the thing before, and it 13 doesn't work out. And so aside from many 14 other things I've got to do, I end up not 15 getting paid. 16 BY MR. PIFKO: 17 Q. Give me some leeway. I don't 18 know if I use all the right terminology here. 19 But if I want to ask, like, so you have -- 20 not every peer-reviewed article is about 21 original research. I mean, maybe you do like 22 a -- you know, maybe you -- what -- I guess 23 what I'm -- I want to talk about data-driven 24 research where you're collecting the data</p>	<p style="text-align: right;">Page 57</p> <p>1 A. The research that I do, some of 2 it is funded by NIH grants. Others of it is 3 unfunded research, I just do it because, as 4 part of my faculty appointment at Harvard, 5 I'm -- you know, I'm paid to teach and do 6 research, and so I just do research through 7 my salary basically. 8 BY MR. PIFKO: 9 Q. Okay. And what I'm trying to 10 get at is any of those research projects, are 11 aspects of the research -- maybe you 12 personally don't get a check, but is parts of 13 the research funded by any private 14 corporations outside of the university? 15 A. I see. 16 MS. MCENROE: Objection to 17 form. 18 A. So some of the -- some of the 19 papers on my CV and -- some of the papers on 20 my CV reflect projects where it would have 21 been a project that I did with Precision 22 Health Economics, and that would have been 23 often, but maybe not always, funded by an 24 industry sponsor. And they are, you know,</p>

<p style="text-align: right;">Page 58</p> <p>1 very clearly -- often there's even industry 2 authors that will -- it's a collaborative 3 effort, we work with industry authors, we 4 write a paper and disclose the funding as 5 well. And some of the work in my CV reflects 6 that kind of research.</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. And the companies that have 9 made those type of payments, we talked about 10 those already?</p> <p>11 A. That's correct.</p> <p>12 Q. There's no other companies that 13 have provided that kind of funding that you 14 can think of sitting here today?</p> <p>15 MS. MCENROE: Objection to 16 form.</p> <p>17 A. There may be other companies, 18 but I think that that's probably a pretty 19 exhaustive list. I would defer to you to 20 look through the papers and see if there's 21 any other sources, but I think that that's 22 pretty accurate.</p> <p>23 BY MR. PIFKO:</p> <p>24 Q. Okay. Well, I'm just asking,</p>	<p style="text-align: right;">Page 60</p> <p>1 because of my expertise. I have a PhD in 2 economics, a medical degree, I see patients, 3 I write about economic issues in health care, 4 and so my background lends itself very well 5 to this kind of work.</p> <p>6 Q. So someone from Analysis Group 7 made a cold call to you and asked if you 8 wanted to be involved with them?</p> <p>9 A. Someone in Analysis Group 10 reached out to me through a mutual 11 acquaintance.</p> <p>12 Q. Okay. Do you remember their 13 name?</p> <p>14 A. Yes. Stephen Fink.</p> <p>15 Q. He works at Analysis Group?</p> <p>16 A. Yes.</p> <p>17 Q. Then I want to ask you, sorry, 18 Precision Health Economics, do you have an 19 official position there?</p> <p>20 A. What do you mean by "official 21 position"?</p> <p>22 Q. Do you have a title being 23 affiliated with --</p> <p>24 A. I think if you look at their</p>
<p style="text-align: right;">Page 59</p> <p>1 we're in the deposition setting, that's all 2 you can remember today?</p> <p>3 A. That's correct.</p> <p>4 Q. Do you intend to continue doing 5 litigation consulting?</p> <p>6 MS. MCENROE: Objection to 7 form.</p> <p>8 A. I plan to continue to do it, 9 but it depends on what other opportunities 10 come my way in terms of research and family 11 obligations and things like that.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. Let's talk about how you came 14 to be retained in this matter, okay?</p> <p>15 A. Sure.</p> <p>16 Q. When did you first -- well, 17 actually, scratch that.</p> <p>18 I want to ask you, how did you 19 first come to be involved with Analysis 20 Group?</p> <p>21 A. I started working with Analysis 22 Group, I believe, sometime in 2018. I may 23 have been approached by them either late -- 24 very late 2017 or early 2018, primarily</p>	<p style="text-align: right;">Page 61</p> <p>1 website, they may say something like research 2 affiliate or something like that. You know, 3 it's probably pretty standard, just like I 4 could be a fellow at some institution. I'm 5 not like a VP of something or senior 6 director. If that's what you mean by 7 "title," then no. But there would be my name 8 on a website, I'm assuming, plus something 9 after it.</p> <p>10 Q. Okay. Right.</p> <p>11 So what I was trying to get at 12 is, do you view yourself as having any sort 13 of formal employment, ongoing employment with 14 Precision Health Economics?</p> <p>15 MS. MCENROE: Objection to 16 form.</p> <p>17 A. I view myself as being a 18 consultant to them. So I can stop consulting 19 with them today or tomorrow without 20 any problem. I don't get any health benefits 21 or anything like that from them, so they're 22 not an employer at all the same way that 23 Harvard or Mass General is an employer of 24 mine.</p>

<p style="text-align: right;">Page 62</p> <p>1 Q. Okay. So Stephen Fink reached 2 out to you from Analysis Group? 3 A. That's correct. 4 Q. And he knew someone else that 5 you knew? 6 A. That's correct. 7 Q. Who was that person there? 8 A. That's his wife. I knew -- his 9 wife is a physician at Mass General. 10 Q. What's her name? 11 A. Sarah Turbett, T-U-R-B-E-T-T. 12 Q. So Stephen Fink reached out to 13 you and said, hey, would you like to start 14 doing some litigation consulting through 15 Analysis Group?</p> <p>16 MS. MCENROE: Objection to 17 form.</p> <p>18 A. Stephen Fink reached out and 19 said, are you -- have you ever done any 20 litigation consulting work before, and I said 21 no, I had not done litigation work before, 22 I'd done other consulting. And I was curious 23 about the types of work that happens in this 24 space, which is obviously old news to you but</p>	<p style="text-align: right;">Page 64</p> <p>1 this is an interesting line of work, the 2 questions that are being asked are really 3 important. 4 And I spend a lot of my time, 5 for lack of better words, in data, in theory. 6 Being able to be part of litigation allows me 7 to take the stuff that I think about in a 8 room where I'm working with a computer and 9 writing papers and writing policy pieces to 10 be able to translate into real life. 11 And so when I left that 12 meeting, I thought this is quite interesting. 13 It's -- you know, I've never been involved in 14 this kind of work before. I can see how the 15 way I think about the world, the questions 16 that I've asked, the answers that I've found 17 in my research could be impactful in shaping 18 how actual things happen in the real world. 19 BY MR. PIFKO: 20 Q. And then six months or so later 21 he called you with a specific assignment? 22 A. I think the first -- the first 23 assignment was what you see there, which was 24 the antitrust matter. And my guess is that</p>
<p style="text-align: right;">Page 63</p> <p>1 was news to me at that time, and I thought it 2 was an area where the set of skills that I've 3 developed and the expertise could actually be 4 very helpful. 5 BY MR. PIFKO: 6 Q. And so did you meet with him in 7 person, or just talk on the phone at that 8 time? 9 A. I think we probably met in 10 person. 11 Q. Then did he ask you to start 12 work on a specific project right away at that 13 time? 14 A. No. It probably would have 15 been months, maybe six, seven months before I 16 actually did any work. 17 Q. So you left that meeting 18 basically telling him, yeah, I'm interested 19 in doing this kind of work, if you have 20 something that -- where someone needs my 21 expertise, I'd be happy to be involved? 22 MS. MCENROE: Objection to 23 form. 24 A. Yeah, I left the meeting saying</p>	<p style="text-align: right;">Page 65</p> <p>1 at the time Analysis Group was working with 2 another law firm on this matter, and they 3 were at the point of the work where they were 4 trying to identify experts. 5 And I had told Steve -- I was 6 like, Steve, I'm interested in this kind of 7 work, things that are health care-related, 8 things that rely on the economics of 9 innovation, things that rely on issues of 10 defining health care markets, things that 11 rely on issues of physician behavior and 12 prescribing and opioids. I've done a lot of 13 work on opioids. This had not started at 14 that point yet. Things of that nature I'd be 15 interested in. 16 And so I suspect, although I 17 don't know the mechanics of what happened on 18 their end, is that they put my name forth as 19 an expert -- potential expert to the law 20 firm, and sometime after that I was retained 21 in that matter. 22 (Whereupon, Jena Exhibit Number 23 1 was marked for identification.)</p>

<p style="text-align: right;">Page 66</p> <p>1 BY MR. PIFKO: 2 Q. I'm handing you what's marked 3 as Exhibit 1. 4 A. Thank you. 5 Q. Which is -- 6 MS. MCENROE: Thank you. 7 BY MR. PIFKO: 8 Q. -- Appendix B to the expert 9 report you provided in this case, which is 10 the list of testimony. Take a minute to look 11 at that, and let me know when you're done. 12 A. All set. 13 Q. So is this a true and correct 14 list of matters where you provided testimony? 15 A. That's correct. 16 Q. So the antitrust litigation, 17 that was the first matter that you worked on? 18 A. Yes. 19 Q. Do you know who the law firm 20 was for that? 21 A. I think Kirkland & Ellis. 22 Q. Do you remember the names of 23 the lawyers that you worked with? 24 A. No. I remember the names of</p>	<p style="text-align: right;">Page 68</p> <p>1 side, do you remember the name of the law 2 firm on the other side, or any of the 3 lawyers' names? 4 A. No. 5 Q. All right. Let's go to the 6 second matter, the Ranbaxy matter. Do you 7 remember the name of the law firm? 8 A. That was -- those two are the 9 same law firms. 10 Q. Okay. That was Kirkland & 11 Ellis as well? 12 A. Yes. 13 Q. Do you remember any of the 14 names on that one? 15 A. And it would have been the same 16 counsel on there. 17 Q. How about on that arbitration 18 matter, the Ranbaxy matter, do you remember 19 the name of the lawyers on the other side? 20 A. No, nor the firm. 21 Q. Okay. And then the Amphastar 22 matter, do you know the name of the law firm 23 that hired you? 24 A. No, I do not know the name of</p>
<p style="text-align: right;">Page 67</p> <p>1 the lawyers in this room, but I couldn't tell 2 you the names of all the different -- no 3 disrespect to counsel -- I don't remember the 4 name of all the lawyers. 5 Q. Okay. You don't remember any 6 of their names? 7 A. Let me just look at this list 8 here. 9 Q. Just on -- but just on that 10 matter. 11 A. For this one, if I give you 12 first names, is that okay? 13 Q. Yeah. 14 A. Devora. 15 Q. Whatever you remember. 16 A. Devora, D-E-V-O-R-A. Oh, yeah, 17 no -- 18 Q. Okay. 19 A. -- that's the extent of my 20 recollection. 21 Q. Do you know what office, in 22 what city? 23 A. New York, that I know. 24 Q. How about lawyers on the other</p>	<p style="text-align: right;">Page 69</p> <p>1 the law firm. 2 Q. How about any of the lawyers? 3 A. No. 4 Q. How about the law firm on the 5 other side? 6 A. Definitely not that. 7 Q. Okay. And so then looking at 8 these, in the antitrust matter, you only 9 provided a deposition, you didn't testify in 10 trial? 11 A. That's correct. 12 Q. Do you know the outcome of that 13 case? 14 A. I believe it's still ongoing. 15 Q. Do you know if any motions were 16 filed to exclude you or -- 17 A. No motions have been filed in 18 any of these matters to exclude me. 19 Q. Okay. The Ranbaxy matter, do 20 you know the outcome of that matter? 21 A. That was an arbitration. I 22 don't know the -- so I know that there was an 23 outcome. I just don't know what the outcome 24 was.</p>

<p style="text-align: right;">Page 70</p> <p>1 Q. Okay. You don't know if there 2 was a finding in favor or against your 3 client?</p> <p>4 A. I think there was a finding in 5 favor of my client, but I'm -- again, I don't 6 know exact details of what that would look 7 like. But I do know that there was an 8 outcome because there was an arbitration, 9 there was some period of time after the 10 arbitration they were supposed to come up 11 with some ruling or some judgment.</p> <p>12 Q. Okay. And then the Amphastar 13 matter, do you know the outcome of that 14 matter?</p> <p>15 A. This matter is still ongoing.</p> <p>16 Q. Do you know if there were any 17 motions to exclude you --</p> <p>18 A. No.</p> <p>19 Q. -- or challenge your testimony?</p> <p>20 A. No motions of that sort have 21 ever been filed against me.</p> <p>22 Q. And then so -- and the 23 Amphastar matter, you testified in 24 deposition, but that was it?</p>	<p style="text-align: right;">Page 72</p> <p>1 BY MR. PIFKO:</p> <p>2 Q. So off the record we were just 3 discussing the litigation consulting where 4 you have not filed a report. And I 5 understand that you're -- you do not 6 understand yourself to be able to -- to 7 identify the clients, is that correct?</p> <p>8 A. That's correct.</p> <p>9 MS. MCENROE: Object to form.</p> <p>10 A. I apologize.</p> <p>11 That's correct.</p> <p>12 MS. MCENROE: And I just want 13 to make sure it's clear, it's not that 14 he's not able to identify who they 15 are, it's that their identities are 16 confidential at this point.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. Let's talk about how you came 19 to be retained in this particular matter, 20 okay?</p> <p>21 A. Sure.</p> <p>22 Q. So when were you first 23 contacted about providing work in the opioid 24 litigation?</p>
<p style="text-align: right;">Page 71</p> <p>1 A. The trial has not occurred yet.</p> <p>2 Q. And then in the Ranbaxy matter, 3 you gave a deposition, and then you also 4 testified at the arbitration hearing?</p> <p>5 A. I think that those are one and 6 the same. But again, I -- I believe that 7 they're one and the same. I think what I did 8 is I filed a report and then gave a testimony 9 and was questioned in an arbitration. I 10 don't think I did something else formal 11 before that.</p> <p>12 Q. Okay.</p> <p>13 MS. MCENROE: Mark, when we 14 reach a good chance to take a quick 15 break, I would appreciate it.</p> <p>16 MR. PIFKO: We can take a 17 break.</p> <p>18 THE VIDEOGRAPHER: The time is 19 12:07 p.m., and we're off the record.</p> <p>20 (Whereupon, a recess was 21 taken.)</p> <p>22 THE VIDEOGRAPHER: The time is 23 12:22 p.m., and we're on the record.</p>	<p style="text-align: right;">Page 73</p> <p>1 A. I think sometime in 2018.</p> <p>2 Q. Who first contacted you?</p> <p>3 A. I believe I was first contacted 4 by Analysis Group.</p> <p>5 Q. Who at Analysis Group?</p> <p>6 A. I'm not sure who it would be, 7 but quite possibly Stephen Fink.</p> <p>8 Q. What did he tell you at that 9 time?</p> <p>10 MS. MCENROE: Objection to 11 form.</p> <p>12 A. At that time probably just 13 described the litigation. I was aware that 14 litigation was ongoing, and he described to 15 me a potential client who may be interested 16 in hearing, you know, my thoughts on these 17 issues. That would have been the nature of 18 the discussion.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. You were aware that the opioid 21 litigation was going on?</p> <p>22 A. I think I was vaguely aware. I 23 may -- and I don't know the timing of it, but 24 I think I was vaguely aware that something</p>

<p>1 was going on.</p> <p>2 Q. What did you understand about</p> <p>3 the opioid litigation around this time --</p> <p>4 MS. MCENROE: Objection to</p> <p>5 form.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. -- when you were first being</p> <p>8 asked to work on this matter?</p> <p>9 A. At a very cursory level, that</p> <p>10 organizations were being sued by local</p> <p>11 jurisdictions.</p> <p>12 Q. Where was the basis of that</p> <p>13 understanding?</p> <p>14 A. Just news media.</p> <p>15 Q. Had you developed a particular</p> <p>16 interest in the litigation at that time</p> <p>17 independent of being retained to work on it?</p> <p>18 MS. MCENROE: Objection to</p> <p>19 form.</p> <p>20 A. No particular interest in the</p> <p>21 litigation. I work -- as you can see from my</p> <p>22 CV, I work a lot on opioids and have done so</p> <p>23 for years. So when Analysis Group approached</p> <p>24 me about this potential matter, you know, I</p>	<p>Page 74</p> <p>1 time beginning with that first call?</p> <p>2 A. I think I probably would have</p> <p>3 started writing down my time after I was</p> <p>4 retained. So usually if I have a call with</p> <p>5 someone, I don't write down the time because</p> <p>6 I haven't been retained and there's no</p> <p>7 expectation. But after I would have been</p> <p>8 retained formally, then I would have started</p> <p>9 writing down time.</p> <p>10 Q. Okay. So you -- do you have a</p> <p>11 sense of when this first call might have</p> <p>12 been?</p> <p>13 A. I don't. Sometime in 2018.</p> <p>14 But the invoices will actually be very clear</p> <p>15 on that, I think.</p> <p>16 Q. Well, that's what I was getting</p> <p>17 at.</p> <p>18 If we look at the invoices --</p> <p>19 so it's your testimony that that invoice</p> <p>20 likely would not reflect this first call</p> <p>21 because you hadn't formally been retained</p> <p>22 yet?</p> <p>23 A. The initial call? I suspect</p> <p>24 not, but, again, I'd have to look at the</p>
<p>Page 75</p> <p>1 was a good fit for it because I've thought a</p> <p>2 lot about these issues, I know about the</p> <p>3 medicine, the economics, the health policy</p> <p>4 issues that are involved, and I've written</p> <p>5 about these issues as well.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. And so Stephen Fink or somebody</p> <p>8 from Analysis Group spoke to you, and you</p> <p>9 said you wanted to be involved?</p> <p>10 A. When they spoke to me, I said</p> <p>11 this is an interesting case, I'd like to</p> <p>12 learn more.</p> <p>13 Q. Okay. And then who did you</p> <p>14 talk to?</p> <p>15 A. At some point I would have</p> <p>16 spoken to counsel from Morgan Lewis. And I</p> <p>17 don't recall who was on the initial call.</p> <p>18 Could be these individuals here. But I had a</p> <p>19 call with Morgan Lewis. Analysis Group was</p> <p>20 also on the phone call, and I -- then I heard</p> <p>21 what some of the issues were.</p> <p>22 Q. We have your invoices, which</p> <p>23 I'll go over with you in a little bit. But</p> <p>24 would you have started to write down your</p>	<p>Page 77</p> <p>1 invoice and see. I mean, I can just tell you</p> <p>2 as a general matter on these matters, for</p> <p>3 lack of better words, I usually don't charge</p> <p>4 a bill for -- you know, bill for that first</p> <p>5 call because I haven't been retained yet.</p> <p>6 But it kind of depends on the context.</p> <p>7 And I've also looked at</p> <p>8 guidance from Analysis Group to say, well,</p> <p>9 should I bill for this call or not. And that</p> <p>10 -- so I don't know exactly in this matter</p> <p>11 what I would have done, but that's my general</p> <p>12 policy towards these things.</p> <p>13 Q. Okay. And then at some point</p> <p>14 after that call you became formally retained?</p> <p>15 A. That's correct.</p> <p>16 Q. What did you understand the</p> <p>17 scope of your assignment to be?</p> <p>18 A. When I was initially retained,</p> <p>19 I was retained not with a specific assignment</p> <p>20 at that time. I think my assignment became</p> <p>21 more clear -- the scope of the assignment</p> <p>22 became more clear later in either late 2018</p> <p>23 or probably closer to early 2019, which is</p> <p>24 when I really went in earnest in developing</p>

<p style="text-align: right;">Page 78</p> <p>1 my report.</p> <p>2 Q. When you did come to an</p> <p>3 understanding about what the scope of work</p> <p>4 was, what was your understanding of what the</p> <p>5 scope of work was?</p> <p>6 MS. MCENROE: Objection to</p> <p>7 form.</p> <p>8 A. So I can -- I could point you</p> <p>9 to the specific part of my assignment, but</p> <p>10 there's basically three broad categories.</p> <p>11 First was to assess a</p> <p>12 particular plaintiff's expert, Dr. McCann, in</p> <p>13 the nature of a suspicious order flagging</p> <p>14 methodology and just to assess it from an</p> <p>15 academic perspective; is this a credible</p> <p>16 methodology or not? Would it pass muster</p> <p>17 based on reliance on scientific evidence and</p> <p>18 methods? And my short answer to that is no.</p> <p>19 The second was to assess the</p> <p>20 quality of Rite Aid's anti-diversion</p> <p>21 practices.</p> <p>22 And the third was to assess the</p> <p>23 harm, if any, that would have arisen from</p> <p>24 Rite Aid's practices as it relates to</p>	<p style="text-align: right;">Page 80</p> <p>1 BY MR. PIFKO:</p> <p>2 Q. I'm going to be handing you</p> <p>3 some materials that were provided to me</p> <p>4 yesterday by counsel for Rite Aid.</p> <p>5 (Whereupon, Jena Exhibit Number</p> <p>6 2 was marked for identification.)</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. The first thing I'm handing you</p> <p>9 is what's marked as Exhibit 2.</p> <p>10 A. Thank you.</p> <p>11 THE WITNESS: I have five</p> <p>12 copies.</p> <p>13 MS. MCENROE: Oh, yeah.</p> <p>14 MR. PIFKO: Let's go off the</p> <p>15 record so we can collate these.</p> <p>16 THE VIDEOGRAPHER: The time is</p> <p>17 12:31 p.m. We're off the record.</p> <p>18 (Whereupon, a recess was</p> <p>19 taken.)</p> <p>20 THE VIDEOGRAPHER: The time is</p> <p>21 12:36 p.m., and we're on the record.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. Okay. You have in front of you</p> <p>24 what's marked as Exhibit 2, which are some</p>
<p style="text-align: right;">Page 79</p> <p>1 diversion from harm.</p> <p>2 Those are the three kind of</p> <p>3 cornerstones of my assignment.</p> <p>4 Q. When you first became retained,</p> <p>5 if you didn't have a clear scope of work,</p> <p>6 what did you understand yourself -- what did</p> <p>7 you understand you were supposed to be doing?</p> <p>8 MS. MCENROE: Objection to</p> <p>9 form.</p> <p>10 A. When I was first -- from the</p> <p>11 period when I was first retained until when I</p> <p>12 started working in earnest on the report,</p> <p>13 there's a series of consulting work that was</p> <p>14 done by Rite Aid, which I was pretty</p> <p>15 peripherally involved. There may be some</p> <p>16 topics here that I would chime in on, but I</p> <p>17 really wasn't fully engaged until the last</p> <p>18 several months where I started working on my</p> <p>19 report.</p> <p>20 MS. MCENROE: Mark, I think</p> <p>21 they should be chronologically</p> <p>22 ordered.</p> <p>23 MR. PIFKO: Okay. We'll find</p> <p>24 out.</p>	<p style="text-align: right;">Page 81</p> <p>1 materials that I received yesterday. Take a</p> <p>2 minute to review those, and let me know when</p> <p>3 you're done.</p> <p>4 A. I've reviewed them.</p> <p>5 Q. For the record, Exhibit 2 is</p> <p>6 six pages. Can you tell me what Exhibit 2</p> <p>7 is?</p> <p>8 A. So Exhibit 2 appears to be</p> <p>9 timesheet that I e-mail to Analysis Group for</p> <p>10 my work on --</p> <p>11 PHONE PARTICIPANT: Sorry to</p> <p>12 interrupt, but we're having trouble,</p> <p>13 at least on my end, hearing you guys</p> <p>14 over the phone.</p> <p>15 THE VIDEOGRAPHER: The time is</p> <p>16 12:37 p.m. We're off the record.</p> <p>17 (Off the record discussion.)</p> <p>18 THE VIDEOGRAPHER: The time is</p> <p>19 12:39 p.m., and we're on the record.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. Okay. So looking at Exhibit 2,</p> <p>22 you said that you e-mail your time to</p> <p>23 Analysis Group?</p> <p>24 A. That's correct.</p>

<p style="text-align: right;">Page 82</p> <p>1 Q. Did you prepare Exhibit 2? 2 MS. MCENROE: Objection to 3 form. 4 A. This is -- these spreadsheets 5 are what I send them, or I have been sending 6 them since, it looks like, April of 2018. I 7 didn't do any additional preparation of these 8 myself. 9 BY MR. PIFKO: 10 Q. Okay. So you -- this is a 11 form -- the same format that you use? You 12 put it into like an Excel file and send it to 13 them? 14 A. Yeah, it looks like actually 15 the exact -- exact format. 16 Q. Okay. So does this reflect all 17 the work that you performed on the case -- 18 MS. MCENROE: Objection to 19 form. 20 BY MR. PIFKO: 21 Q. -- to date? 22 A. This reflects the work as of 23 April 30, 2019. So any work that would have 24 been done the month of May I have not</p>	<p style="text-align: right;">Page 84</p> <p>1 that was the initial call per our earlier 2 conversation, or whether this is a follow-up 3 call that might have happened sometime later. 4 I would imagine that the proximity between 5 this date and when I was retained would have 6 been pretty close. 7 Q. So you likely would have been 8 retained sometime in April, 2018? 9 A. Yeah, sometime in March or 10 April, 2018. 11 Q. And then you said you didn't 12 really get started on the report until 13 sometime later. Looking at these time 14 entries, when would you say you started 15 working on the report? 16 MS. MCENROE: Objection to 17 form. 18 A. So looking at the time entries, 19 looks like March of 2019. 20 BY MR. PIFKO: 21 Q. So the work that you did prior 22 to March, 2019 is not related to forming your 23 opinions that are in your report? 24 MS. MCENROE: Objection to</p>
<p style="text-align: right;">Page 83</p> <p>1 submitted any timesheet on. 2 Q. Okay. So other than the month 3 of May, does that reflect all the work that 4 you've done? 5 MS. MCENROE: Objection to 6 form. 7 A. Yeah, month of May and month of 8 June, which is a few days. 9 BY MR. PIFKO: 10 Q. So these are true and correct 11 copies of all the work you performed before 12 May, 2019 on this matter? 13 MS. MCENROE: Objection to 14 form. 15 A. Yes, before -- on or before 16 April 30, 2019, that's correct. 17 BY MR. PIFKO: 18 Q. Looking at the first page of 19 Exhibit 2, does this refresh your 20 recollection about when you were retained in 21 this matter? 22 A. What I can see here is that on 23 April 27, 2018, I billed half an hour for a 24 counsel call. I don't recall whether or not</p>	<p style="text-align: right;">Page 85</p> <p>1 form. 2 A. The opinions that are in my 3 report relate to a specific assignment that I 4 was asked to do. The work that predates that 5 was consulting work that I was kind of 6 peripherally involved in. It helped build 7 awareness of some of the issues. 8 So, for instance, there's data 9 sets that I rely on in my report, like the 10 ARCOS data, that I probably would have seen 11 prior to March of 2019, which is incredibly 12 helpful because you can't just analyze a data 13 set in one week and expect to know what it 14 entails. 15 So there's part of the 16 report -- parts of the billings before March 17 of 2019 that would have been relevant, but my 18 report relates to a specific assignment, and 19 that assignment was not handed down to me 20 until, you know, sometime probably in March, 21 I would guess. 22 BY MR. PIFKO: 23 Q. Of 2019? 24 A. Of 2019, yes.</p>

<p style="text-align: right;">Page 86</p> <p>1 Q. The last month -- prior to 2 March, 2019, the last time you worked on the 3 case was July 20, 2018, is that correct? 4 MS. MCENROE: Objection to 5 form. 6 A. That looks correct. 7 BY MR. PIFKO: 8 Q. You didn't do anything on the 9 case between July 20, 2018 and March 18, 10 2019, correct? 11 A. Not -- 12 MS. MCENROE: Objection to 13 form. 14 A. Not that I'm aware of. 15 BY MR. PIFKO: 16 Q. You finalized your report on 17 May 10th? 18 A. That sounds right. I'd have to 19 look at the report, but that sounds right. 20 Q. The last entry on Exhibit 2 is 21 April 30, 2019. Agree? 22 A. I agree with that. 23 Q. Okay. Let's talk about the 24 work that you did after that up until</p>	<p style="text-align: right;">Page 88</p> <p>1 Do you understand the 2 difference? 3 A. Understood. 4 Q. Okay. So when you say that you 5 worked 20 to 30 hours in May, that's an 6 estimate? 7 A. I would estimate that between 8 the dates of April 30th to the filing of the 9 report on May 10th, my estimate is that I 10 worked 20 to 30 hours. 11 Q. Okay. And you have recorded 12 your time just like you did on Exhibit 2, but 13 you just haven't sent a bill for that yet? 14 A. That is correct. 15 Q. Have you sent that to Analysis 16 Group yet? 17 A. No. 18 Q. What's the protocol that you 19 use to send your time to Analysis Group? 20 MS. MCENROE: Objection to 21 form. 22 A. Sometimes I will e-mail a 23 document at the end of the month or in the 24 first week of the following month. Other</p>
<p style="text-align: right;">Page 87</p> <p>1 finalizing your report, okay? 2 A. Sure. 3 Q. Do you know about how many 4 hours you spent, well, in May working on your 5 report? 6 A. So between April 30th to 7 May 10th, if I had to guess, I would say 8 probably maybe 20 to 30 hours, if I had to 9 guess, somewhere in that ballpark. 10 to 10 30 hours. It's a broad range, I realize, but 11 that's obviously a busy time. 12 Q. So just for clarity, I don't 13 want you to guess in the deposition, and 14 maybe that's just a term that lawyers use, 15 but you are allowed to provide an estimate. 16 But a guess is just a shot in the dark like, 17 you know -- 18 A. I see. 19 Q. -- I don't have -- if I just 20 would have guessed how much money you have in 21 your wallet, I have no idea, versus 22 estimating how much money I might have in my 23 wallet, I might not know the exact number but 24 I probably could have a good estimate.</p>	<p style="text-align: right;">Page 89</p> <p>1 times, if there's a clear goal, benchmark or 2 goalpost, I'll wait until that. 3 So, for instance, if there's a 4 deposition on June 10th, I probably would not 5 have -- I probably would have waited until 6 after the deposition because I would not 7 expect any other subsequent work to be done 8 on that project. So that just saves the 9 hassle of having to send two different 10 invoices. 11 BY MR. PIFKO: 12 Q. Okay. So what I'm hearing you 13 say basically is -- today is June 5th, is 14 that correct? 15 A. That's correct. 16 MS. MCENROE: Objection. 17 It's June 6th. 18 BY MR. PIFKO: 19 Q. Okay. June 6th. All right. 20 So given that we're only a few 21 days into June, you're going to submit your 22 May time along with the work up until now not 23 long after, and then just have one invoice? 24 A. So --</p>

<p style="text-align: right;">Page 90</p> <p>1 MS. MCENROE: Objection to 2 form. 3 A. So I'll submit sometime after 4 today because I haven't submitted it yet, and 5 it depends on what else I have to do. 6 And sometimes Analysis Group 7 may reach out to me and say, oh, have you 8 sent us your, you know, billings for this 9 month, and I would say, oh, I completely 10 forgot because I've got other things I've got 11 to take care of. 12 BY MR. PIFKO: 13 Q. Do you have a document where 14 you've been putting in your May time? 15 A. Not yet, in part because I kind 16 of go back retrospectively and try to figure 17 out what I would have been doing on these 18 different dates. I should probably have a 19 better bookkeeping method than I do. But not 20 yet. 21 Q. In preparing for this 22 deposition, did you look at anything to give 23 you a sense of how much time you spent in May 24 working on the report?</p>	<p style="text-align: right;">Page 92</p> <p>1 Q. Okay. So you saw invoices from 2 Analysis Group in preparing for this 3 deposition? 4 A. I saw invoices yesterday. My 5 understanding is that a court order was -- 6 there's a court order to produce these 7 invoices, and so yesterday was the first time 8 I've ever seen any sort of invoice from 9 Analysis Group to Rite Aid, much less any 10 other client. 11 Q. Did you work with anybody on 12 the report who didn't work at Analysis Group? 13 A. No. 14 Q. After May 10th, or whenever the 15 date that you finished your report, between 16 then and now, did you do any work for the 17 case? 18 MS. MCENROE: Objection to 19 form. 20 A. Yes. 21 BY MR. PIFKO: 22 Q. What did you do? 23 A. Primarily preparation for the 24 deposition.</p>
<p style="text-align: right;">Page 91</p> <p>1 A. Not explicitly. 2 Q. What was the nature of the work 3 that you did in May on your report on this 4 estimated 20 to 30 hours? 5 MS. MCENROE: Objection to 6 form. 7 A. From the period of May 30 until 8 I filed the report, it would have been 9 continuing to edit the manuscript or edit the 10 report, going through performing additional 11 analyses, reviewing materials that I relied 12 on on the report, that sort of stuff. 13 BY MR. PIFKO: 14 Q. And did you work with others in 15 drafting the report? 16 A. I did. 17 Q. And those are people who work 18 at Analysis Group? 19 A. That's correct. 20 Q. Have you seen their invoices to 21 counsel or Rite Aid? 22 A. I saw invoices yesterday, but 23 prior to that I'd never seen any invoices 24 from them.</p>	<p style="text-align: right;">Page 93</p> <p>1 Q. What did you do to prepare for 2 the deposition? 3 A. I did a few things. One is I 4 went through my report multiple times so I 5 could make sure that I could streamline the 6 process of our discussion with relationship 7 to the report. 8 Two is I re-reviewed and 9 re-reviewed again the materials that I rely 10 on. I looked back at the analysis to make 11 sure that I could explain it very clearly and 12 succinctly if I'm asked about it. 13 And that's about it. That's 14 been the nature of my preparation. 15 Q. Did you meet with counsel to 16 prepare for the deposition? 17 A. I did. 18 Q. When was that? 19 A. I met yesterday as well as last 20 week, I believe. I met twice with them. 21 Q. Yesterday, was that in person? 22 A. Yes, that was in person. 23 Q. Last week, was that in person? 24 A. That was in person.</p>

Page 94	Page 96
<p>1 Q. Was that here in Boston last 2 week?</p> <p>3 A. That was here in Boston.</p> <p>4 Q. And was that -- those meetings 5 with counsel that's present here today?</p> <p>6 A. Yes.</p> <p>7 Q. Anyone else?</p> <p>8 A. Last week counsel named Kelly 9 Moore was here as well.</p> <p>10 Q. Okay. Yesterday she wasn't 11 here?</p> <p>12 A. She was not here yesterday.</p> <p>13 Q. Did you speak with Kelly prior 14 to meeting with her last week?</p> <p>15 A. I have spoken to her on the 16 phone before.</p> <p>17 Q. Was there anyone else present 18 at the meeting last week besides Kelly and 19 counsel who is here today?</p> <p>20 A. Two members from Analysis Group 21 were also present.</p> <p>22 Q. Who was that?</p> <p>23 A. Stephen Fink, and a woman named 24 Erica VanSant, V-A-N-S-A-N-T.</p>	<p>1 Q. Was there anyone from Analysis 2 Group at that meeting?</p> <p>3 A. At that meeting, the same 4 individuals were present as I just described.</p> <p>5 Q. Stephen and Erica?</p> <p>6 A. Yes.</p> <p>7 Q. The materials you relied upon 8 in forming your opinions, so some of them are 9 publicly available materials, some might be 10 materials that you're aware of from your 11 academic experience, but other materials are 12 from the litigation, correct?</p> <p>13 A. That's correct.</p> <p>14 Q. Okay. How did you obtain the 15 materials from the litigation?</p> <p>16 A. I formulated an outline of what 17 I wanted to address in the report, and asked 18 my colleagues that I supervise at Analysis 19 Group to identify documents -- they were all 20 available to them -- to identify documents 21 that could help elucidate each one of those 22 different points that I wanted to address.</p> <p>23 Q. So looking back to Exhibit 2, 24 the second-to-last page, which is March,</p>
<p>1 Q. Were Stephen and Erica at 2 yesterday's meeting?</p> <p>3 A. They were at yesterday's 4 meeting as well.</p> <p>5 Q. Anyone else?</p> <p>6 A. No.</p> <p>7 Q. So let's just be clear. So 8 yesterday's meeting was Stephen, Erica, John, 9 Elisa, and you?</p> <p>10 A. That's correct.</p> <p>11 Q. Okay. And last week was 12 Stephen, Erica, Kelly. Was Elisa there?</p> <p>13 A. Elisa was there, but John was 14 not there last week.</p> <p>15 Q. Okay. Did you have any other 16 in-person meetings with counsel --</p> <p>17 A. No.</p> <p>18 Q. -- at any time on the case?</p> <p>19 A. Yes, we met once before. That 20 was probably two months ago in Boston.</p> <p>21 Q. Who was present at that 22 meeting?</p> <p>23 A. At that meeting was Elisa 24 McEnroe and Kelly Moore.</p>	<p>1 2019, time, item 4 says there's work on an 2 outline.</p> <p>3 Do you see that?</p> <p>4 A. I see that.</p> <p>5 Q. Okay. Is that the outline that 6 you're talking about?</p> <p>7 A. That is the outline -- I 8 presume that's the outline that I'm talking 9 about.</p> <p>10 Q. So you put together -- at that 11 point you understood what the scope of your 12 assignment was going to be?</p> <p>13 MS. MCENROE: Objection to 14 form.</p> <p>15 A. I'm assuming that when I write 16 here work on the outline, I'm referring to 17 the first instance in which I'm working on 18 it. It's possible that there may be other 19 times that I was working on it. But let's -- 20 I'm estimating that it was around March 22nd, 21 last week of March, and at that time I would 22 have had a good understanding what my 23 assignment would be.</p> <p>24 BY MR. PIFKO:</p>

Page 98	Page 100
<p>1 Q. Okay. And you would have 2 understood that your scope of your assignment 3 was those three areas that we discussed 4 earlier; assessing Dr. McCann, looking at 5 Rite Aid's diversion control programs, and 6 the harm potentially caused by Rite Aid?</p> <p>7 A. That's correct.</p> <p>8 MS. MCENROE: Objection to 9 form.</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. And so then you would have 12 outlined the details of what you wanted to 13 say in your report, and then asked people at 14 Analysis Group to find you documents that are 15 relevant to those issues?</p> <p>16 MS. MCENROE: Objection to 17 form.</p> <p>18 A. I would have outlined 19 details -- I'll just use your words to be 20 specific. I would have outlined details of 21 my report and asked Analysis Group to build 22 out that information with me using evidence 23 that's been produced in this litigation, my 24 own research, and outside documents that are</p>	<p>1 form.</p> <p>2 A. You mean specific on my 3 language? The direction of the report was my 4 direction. The assignment came from counsel.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. When you say the assignment 7 versus the direction, what do you mean by 8 that?</p> <p>9 A. Well, the assignment is a set 10 of topics to answer. The direction of the 11 report is up to me. I can analyze it using 12 publicly available information. I can 13 analyze it using ARCOS data. I can analyze 14 these questions using documents that are 15 produced in litigation. That's under my 16 direction. Which is a different question 17 than what is the questions that I'd like -- 18 counsel would like me to opine upon.</p> <p>19 Q. Okay. So when we talk about 20 the three areas of assessing Dr. McCann, the 21 quality of Rite Aid's diversion control 22 programs, and the potential harm caused by 23 Rite Aid, those came from counsel?</p> <p>24 MS. MCENROE: Objection to</p>
Page 99	Page 101
<p>1 publicly available.</p> <p>2 But prior to that, as you can 3 see, I'd been doing some work in this space 4 and, you know, understood that these are 5 likely to be the issues even without a formal 6 assignment from counsel.</p> <p>7 And so the Analysis Group team 8 has been familiarizing themselves through my 9 direction of a lot of the material, including 10 the data. I mentioned earlier that the ARCOS 11 data is this huge dataset. It takes effort 12 to understand, to debug, to analyze. That 13 kind of analysis was already underway.</p> <p>14 By the end of March is when I 15 had a firm direction of which way the report 16 would go, and so some of the preparatory work 17 that had already been done could now be 18 really done in earnest. And so I asked the 19 Analysis Group team to look into items A, B, 20 C, and D and try to help me build out the 21 evidence base for these different points.</p> <p>22 Q. Who gave you the firm direction 23 about which way the report was going to go?</p> <p>24 MS. MCENROE: Objection to</p>	<p>1 form.</p> <p>2 A. That is correct.</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. Were there any other topics 5 they asked you to look at that you decided 6 not to use in your report?</p> <p>7 MS. MCENROE: Objection to 8 form.</p> <p>9 A. No.</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. Who did you work with at 12 Analysis Group?</p> <p>13 A. I worked with a team. The team 14 is led by Stephen Fink and Erica VanSant. 15 There's a few other research assistants and 16 associates who have also been involved in the 17 work as well.</p> <p>18 Q. Let's discuss some of the 19 people at Analysis Group. In order to do 20 that, I'm going to hand you the materials I 21 was provided yesterday from Analysis Group.</p> <p>22 MS. MCENROE: Mark, just to 23 speed things along, those are 24 organized in the same way the other</p>

<p>1 documents had been.</p> <p>2 MR. PIFKO: Let's take a break</p> <p>3 so that we can organize these.</p> <p>4 THE VIDEOGRAPHER: The time is</p> <p>5 12:59 a.m., and we're off the record.</p> <p>6 (Whereupon, a luncheon recess</p> <p>7 was taken.)</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>Page 102</p> <p>1 description.</p> <p>2 So in many antitrust cases, one</p> <p>3 of the key issues is defining the market, and</p> <p>4 the reason supported to define the market is</p> <p>5 to understand whether the firm has market</p> <p>6 power in that market. And it's actually not</p> <p>7 a trivial exercise to figure out what are the</p> <p>8 different products that comprise the market.</p> <p>9 So, for instance, Levi jeans</p> <p>10 and Lee jeans probably comprise the same</p> <p>11 market, whereas some fancy company, some</p> <p>12 fancier jeans may be in a different market.</p> <p>13 In the pharmaceutical context,</p> <p>14 the opinion that I provided in this</p> <p>15 particular case was trying to use a clinical</p> <p>16 perspective, clinical and economic</p> <p>17 perspective, to define the market.</p> <p>18 And I basically relied on</p> <p>19 clinical guidelines to say what would</p> <p>20 physicians who are faced with a patient who</p> <p>21 has condition X, what are the treatments that</p> <p>22 they would choose between, is it just one</p> <p>23 treatment, two treatments, which would have a</p> <p>24 narrow market, or is it seven or eight</p>
<p>1</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>Page 103</p> <p>1 AFTERNOON SESSION</p> <p>2</p> <p>3 THE VIDEOGRAPHER: The time is</p> <p>4 1:29 p.m., and we're on the record.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. Real quick before we go back to</p> <p>7 the invoices, I want to look at Exhibit 1</p> <p>8 again, your list of testimony.</p> <p>9 A. Yes.</p> <p>10 Q. Are you there?</p> <p>11 A. Yes.</p> <p>12 Q. What were your opinions in the</p> <p>13 antitrust case?</p> <p>14 MS. MCENROE: Objection to</p> <p>15 form.</p> <p>16 And I'm not familiar with that</p> <p>17 litigation, so I don't know if there</p> <p>18 are confidentiality provisions in</p> <p>19 place or a protective order. So I</p> <p>20 just warn, if Dr. Jena believes it's</p> <p>21 confidential, that he shouldn't</p> <p>22 testify to that. But otherwise I</p> <p>23 don't have any basis to say otherwise.</p> <p>24 A. I can give you a high-level</p> <p>Page 105</p> <p>1 treatments, which would imply a broader</p> <p>2 market.</p> <p>3 And then I conducted data</p> <p>4 analysis to look at real world patients and</p> <p>5 to see in those contexts, what are the types</p> <p>6 of drugs that patients choose between, do</p> <p>7 they choose between one or two patients,</p> <p>8 again, which would define the market to be</p> <p>9 narrower, or do they choose between eight or</p> <p>10 nine medications.</p> <p>11 So that's the kind of basic</p> <p>12 analysis that I performed there.</p> <p>13 BY MR. PIFKO:</p> <p>14 Q. Okay. And then ultimately your</p> <p>15 conclusion was that your clients did not have</p> <p>16 market power?</p> <p>17 MS. MCENROE: Objection to</p> <p>18 form.</p> <p>19 A. In this particular case I</p> <p>20 didn't actually come down on market power</p> <p>21 versus not. I was really defining the market</p> <p>22 and looking at economic substitutability.</p> <p>23 So the specific conclusion that</p> <p>24 I had in this particular paper was looking at</p>

<p style="text-align: right;">Page 106</p> <p>1 whether or not the product at issue was an 2 economic or therapeutic substitute with other 3 products. And the way I did that is I said, 4 look at other treatment -- look at treatment 5 guidelines and see whether or not there are 6 other products or not. If there are, then 7 there would be substitutes towards that first 8 product.</p> <p>9 And then the second issue is 10 looking at how patients' demand for the first 11 product at issue relates to the prices of 12 other products. If there's a cross-price 13 elasticity, meaning a sensitivity of demand 14 of the first product with respect to the 15 other ones, that would suggest that there 16 might be economic substitutes.</p> <p>17 So that's what I was opining 18 on, is there economic or clinical 19 substitutability between an at-issue product 20 and the other ones.</p> <p>21 Q. Okay. Did you find that there 22 was economic substitutability for your 23 clients' products?</p> <p>24 MS. MCENROE: Objection to</p>	<p style="text-align: right;">Page 108</p> <p>1 here, it was a very similar issue of what are 2 the therapeutic substitutes to the product. 3 In this case it was a product to treat 4 metabolic disease. And the question was 5 whether or not there are other products that 6 are used to treat metabolic disease, or 7 simply one product.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. And did you find that your 10 clients' -- there was substitutability for 11 your clients' products in this -- in the 12 arbitration case as well?</p> <p>13 MS. MCENROE: Objection to 14 form.</p> <p>15 A. In that case I found that there 16 are other treatment options that are 17 supported by clinical guidelines for the 18 treatment of this particular condition.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. Okay. And then the Amphastar 21 case, what was the nature of your opinions?</p> <p>22 MS. MCENROE: Objection to 23 form. Same objection I made 24 previously regarding confidentiality</p>
<p style="text-align: right;">Page 107</p> <p>1 form.</p> <p>2 A. In this case I found that 3 there's clinical and economic 4 substitutability between that product and 5 other products.</p> <p>6 THE VIDEOGRAPHER: Can we go 7 off for one second? I don't know -- 8 something got tripped with the power. 9 It seems -- now it's back. Sorry.</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. Okay. Going to the Ranbaxy 12 case, what was the nature of your opinions in 13 that case?</p> <p>14 MS. MCENROE: Objection to 15 form. Same objection I made 16 previously regarding potential 17 confidentiality concerns.</p> <p>18 But, Dr. Jena, I leave that to 19 you in terms of whether you have a 20 protective order obligation or not.</p> <p>21 A. I think I can provide a 22 high-level analysis. I wish I remembered 23 more of the details of the case.</p> <p>24 But in this particular case</p>	<p style="text-align: right;">Page 109</p> <p>1 obligations or a protective order, but 2 I leave that up to the witness.</p> <p>3 A. That was a similar sort of case 4 where I was approaching this question to 5 define the market from a clinical 6 perspective. This was a -- also a 7 cardiovascular medication that was at issue 8 here. And the question was whether or not 9 that medication is the only medication that 10 patients use for this particular condition, 11 or do clinical guidelines assert five or six 12 different medications.</p> <p>13 And my finding there was that 14 there's multiple different medications that 15 physicians use.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Okay. So similarly, there was 18 substitutability for those -- your clients' 19 product as well?</p> <p>20 MS. MCENROE: Objection to 21 form.</p> <p>22 A. That's correct. Another way to 23 say it is that the product is not unique in 24 any particular way.</p>

Page 110	Page 112
1 BY MR. PIFKO: 2 Q. Okay. Do you know -- in all 3 these cases, was your client a plaintiff or 4 defendant? Do you know the answer to that? 5 A. In these two cases, I was 6 representing the defendant. 7 Q. Okay. In all three, they were 8 defendants? 9 A. That's correct. 10 (Whereupon, Jena Exhibit Number 11 3 was marked for identification.) 12 BY MR. PIFKO: 13 Q. I'm handing you what's marked 14 as Exhibit 3. 15 A. Thank you. 16 Q. These are invoices from 17 Analysis Group that I received yesterday. 18 Take a moment to review them real quick, and 19 let me know when you're ready. 20 MR. PIFKO: For the record, 21 there are several pages within, but there's 22 one dated May 24, 2018, July 3, 2018, 23 July 27, 2018, August 20, 2018, September 28, 24 2018, October 22, 2018, December 21, 2018,	1 for example, looking at the top invoice from 2 May 24, 2018, the second page, it's got two 3 hours of time for Stephen Fink. 4 Do you see that? 5 A. Yes, I see that on the second 6 page. 7 Q. So you don't know if that's 8 accurate or not, correct? 9 A. I'm not an accountant, and also 10 I'm not filling this invoice, so I can't say 11 if it's accurate or not. I presume that it's 12 accurate, but it's an invoice that I wasn't 13 part of. 14 Q. Okay. But your time -- we can 15 cross-check your time with Exhibit 2 and see 16 that, if you look at the first page of 17 Exhibit 2, April 27, 2018, you billed 18 25 hours, we can see that that is correct, 19 yes? 20 A. Yes. 21 Q. Okay. And you don't have a 22 date -- there isn't a date on the Analysis 23 Group invoice, but it's for the period that 24 ends April 30th, so we can conclude that that
Page 111	Page 113
1 January 25, 2019, February 19, 2019, 2 March 22, 2019, April 29, 2019, and May 21, 3 2019. 4 (Witness reviewing document.) 5 A. Okay. I've reviewed them. 6 BY MR. PIFKO: 7 Q. Okay. So the first time that 8 you saw these was yesterday? 9 A. The first time that I saw an 10 invoice was yesterday. I haven't reviewed 11 all -- you know, multiple of these invoices 12 here. 13 Q. So you don't have any knowledge 14 either way about whether these are true and 15 correct and accurate? 16 A. To the extent that they reflect 17 my own professional hours and those are 18 consistent with what's reported in the 19 spreadsheet, those are an accurate reflection 20 of my work in this matter. I don't -- I'm 21 not involved in the billing of Analysis Group 22 for its own work and services to clients, 23 including Rite Aid. 24 Q. Okay. So you don't know if --	1 .5 is the .5 referenced in your -- 2 MS. MCENROE: Objection to 3 form. 4 BY MR. PIFKO: 5 Q. -- April 27, 2018 invoice, 6 correct? 7 A. I would think so. 8 Q. So other than verifying your 9 time like we just did for the April 30, 2018 10 period, you're not able to verify the 11 accuracy of any of these Analysis Group 12 invoices, correct? 13 MS. MCENROE: Objection to 14 form. 15 A. I can't comment on the accuracy 16 of any billing besides my own. 17 BY MR. PIFKO: 18 Q. Who would be the best person to 19 do that? Mr. Fink? 20 MS. MCENROE: Objection to 21 form. 22 A. I also don't know who the best 23 person at Analysis Group would be to do that. 24

Page 114	Page 116
<p>1 BY MR. PIFKO:</p> <p>2 Q. Okay. But we'd have to talk to</p> <p>3 someone at Analysis Group?</p> <p>4 MS. MCENROE: Objection to</p> <p>5 form.</p> <p>6 A. I presume so. It definitely</p> <p>7 wouldn't be to talk to me.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. I do want to go through,</p> <p>10 however, some of these, and ask you about the</p> <p>11 individuals.</p> <p>12 A. Sure.</p> <p>13 Q. So then go to the July 3, 2018</p> <p>14 invoice, and then you go to Page 3. Tell me</p> <p>15 when you're there.</p> <p>16 A. Okay. I am there.</p> <p>17 MS. MCENROE: I see.</p> <p>18 BY MR. PIFKO:</p> <p>19 Q. All right. So it's got you for</p> <p>20 nine hours. We can cross-check. That's</p> <p>21 consistent with the amount of time you</p> <p>22 billed, if you look back at Exhibit 2,</p> <p>23 correct?</p> <p>24 A. That looks like it's for the</p>	<p>1 matter?</p> <p>2 A. I did.</p> <p>3 Q. What was the nature of your</p> <p>4 work with him?</p> <p>5 MS. MCENROE: Objection to</p> <p>6 form.</p> <p>7 A. This was a period, I believe,</p> <p>8 when Mr. Fink was out, or soon to be, on some</p> <p>9 abbreviated -- a paternity leave, he just had</p> <p>10 twins around this time. And Mr. Kirson was</p> <p>11 involved for some period of time, maybe a</p> <p>12 month or two, in kind of starting the work on</p> <p>13 this Rite Aid matter.</p> <p>14 BY MR. PIFKO:</p> <p>15 Q. Did you consult with him about</p> <p>16 strategies to use in the case?</p> <p>17 MS. MCENROE: Objection to</p> <p>18 form.</p> <p>19 A. I discussed with him what are</p> <p>20 the datasets that are currently being</p> <p>21 produced in the litigation.</p> <p>22 A lot of the early work in this</p> <p>23 matter that you're referencing in this time</p> <p>24 period would have been data-oriented.</p>
<p style="text-align: center;">Page 115</p> <p>1 May period, in May, that looks correct, yes.</p> <p>2 Q. Okay. The next person,</p> <p>3 N. Kirsom, do you know who that is?</p> <p>4 A. Yes.</p> <p>5 Q. What's their full name?</p> <p>6 A. Noam Kirson, N-O-A-M.</p> <p>7 Q. And is that a man or a woman?</p> <p>8 A. That's a man.</p> <p>9 Q. I assumed, but you never know.</p> <p>10 What does he do?</p> <p>11 A. He is also a vice president at</p> <p>12 Analysis Group.</p> <p>13 Q. Do you know what his background</p> <p>14 is?</p> <p>15 A. He has a PhD in economics from</p> <p>16 Harvard.</p> <p>17 Q. He's employed by Analysis</p> <p>18 Group?</p> <p>19 A. I believe so, yes.</p> <p>20 Q. Do you know if he has any other</p> <p>21 degrees?</p> <p>22 A. Besides the PhD? He might, but</p> <p>23 I'm not sure. He does not have an MD.</p> <p>24 Q. Did you work with him on this</p>	<p style="text-align: center;">Page 117</p> <p>1 BY MR. PIFKO:</p> <p>2 Q. Okay. So the work with</p> <p>3 Mr. Kirson was limited to just this early</p> <p>4 period when Mr. Fink was on leave?</p> <p>5 A. We can go through the</p> <p>6 individual invoices just to verify, but we</p> <p>7 can see in the next invoice of July 27,</p> <p>8 Mr. Kirson's name is listed. August 20th,</p> <p>9 his name is no longer listed. September 28th</p> <p>10 invoice, his name is no longer listed.</p> <p>11 Q. I can represent to you I went</p> <p>12 through these. He's only billed time in</p> <p>13 May -- the May 28, 2018, and the June, 2018.</p> <p>14 A. That would be consistent with</p> <p>15 my recollection and also the explanation I</p> <p>16 just provided regarding the paternity leave</p> <p>17 for Mr. Fink.</p> <p>18 Q. Okay. We talked about Stephen</p> <p>19 Fink.</p> <p>20 Who is S. Kim?</p> <p>21 A. I believe that's Soojin Kim.</p> <p>22 Q. Mr. Fink, by the way, what --</p> <p>23 do you know what type of degrees he has?</p> <p>24 A. He has an MBA from Columbia</p>

Page 118	Page 120
<p>1 Business School, and an undergraduate from 2 Vassar College.</p> <p>3 Q. Soojin Kim, do you know the 4 academic background?</p> <p>5 A. I don't know her detailed 6 academic background. I believe she studied 7 economics and is an undergraduate, may have 8 an MBA or a master's degree, but I'm not 9 entirely sure.</p> <p>10 Q. Did you work with Ms. Kim on 11 the matter?</p> <p>12 A. I worked with all these 13 individuals on the matter. Each person has 14 different roles, and the roles vary over 15 time, but I worked with each one of these 16 individuals on the case.</p> <p>17 Q. What was Ms. Kim's role?</p> <p>18 A. It's hard to say as of this 19 period what her role was, but I can outline 20 for you the general roles that I oversaw.</p> <p>21 So one big thing is data 22 cleaning, data preparation, data analysis.</p> <p>23 The second big thing would be 24 analyzing existing documents that have been</p>	<p>1 So, for instance, if you get a 2 data set that's transaction-based and it says 3 1/7/2012, you and I would probably both 4 interpret that to mean January 7, 2012. The 5 next line might say 1-7-2012. In order to 6 analyze data in a systematic way, we have to 7 tell the computer program that both of those 8 entries reflect January 7, 2012. The process 9 of data cleaning is one in which an analyst 10 would go through and write a program to 11 create a data set that can be easily 12 analyzed.</p> <p>13 That's an example of what data 14 cleaning, or data processing is the other 15 term you might hear.</p> <p>16 Q. What type of data analysis did 17 Ms. Kim do?</p> <p>18 MS. MCENROE: Objection to 19 form.</p> <p>20 A. So in this particular case, the 21 data analysis that were conducted -- and she 22 was probably a part of some of this, but it's 23 hard for me to know exactly what part. This 24 is a report and a set of analysis that was</p>
Page 119	Page 121
<p>1 produced in the litigation, looking at 2 publicly available documents, looking at 3 publicly available data.</p> <p>4 The third broad bucket would be 5 in terms of helping drafting particular 6 sections of the report under my direction. 7 For instance, I might say, you know, I've 8 written this paper on XYZ, could you please 9 put that into the report, cite this study, 10 and describe it in the following way. And 11 they would pull the report, introduce it -- 12 pull the study, introduce it into the record, 13 so forth.</p> <p>14 So Ms. Kim, as well as 15 including Mr. Fink, Mr. Kirson, and others 16 that you'll see on subsequent invoices, would 17 probably have all shared roles of those 18 forms.</p> <p>19 Q. When you say "data cleaning," 20 what does that mean?</p> <p>21 A. Data cleaning means the 22 following; if you get a large data set, 23 sometimes the data elements aren't as 24 structured as they should be.</p>	<p>1 conducted over many months over many person 2 hours.</p> <p>3 The core parts of the empirical 4 analysis in my report reflect the ARCOS 5 database, which is a transaction database. I 6 focused on opioid distribution, looking 7 particularly at Dr. McCann's report in which 8 he identified a methodology for flagging 9 potentially suspicious orders.</p> <p>10 So I analyzed the database and 11 said, look, there's five methodologies that 12 Dr. McCann lays out, can we first replicate 13 that methodology. That was the first task, 14 can we replicate what Dr. McCann has done.</p> <p>15 And then, secondly, now let me 16 start and kind of unpack what is the validity 17 of each one of these methodologies. And 18 doing that requires working with the ARCOS 19 data. And that's, I'm sure, what Ms. Kim and 20 Mr. Fink and Mr. Kirson and Mr. Flignor and 21 others had a part in as well.</p> <p>22 Q. So I was going to ask you, the 23 ARCOS data that you examined, are you aware 24 that there's publicly available ARCOS data,</p>

Page 122	Page 124
<p>1 then there's ARCOS data that was produced in 2 the case?</p> <p>3 MS. MCENROE: Objection to 4 form.</p> <p>5 A. I'm aware of that.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. Okay. Which ARCOS data did you 8 review?</p> <p>9 A. The ARCOS -- there's two types 10 of ARCOS data, actually, that I rely on in my 11 report. The first is data that was produced 12 in the case, and that expanded over time. 13 Initially it was in these counties. It's 14 actually national in nature.</p> <p>15 The second is a form that was 16 processed by expert McCann, Dr. McCann. 17 There, he had already processed some of the 18 information. And in order to be consistent 19 with his analysis and to ensure that his 20 analysis was valid, I used the process data 21 that Dr. McCann had used of the ARCOS data.</p> <p>22 Q. You said one of the steps in 23 the process that you used was replicating the 24 analysis that Dr. McCann did. Was your team</p>	<p>1 that name right?</p> <p>2 A. I believe so.</p> <p>3 Q. Okay. What's his full name?</p> <p>4 A. I believe it's Max Flignor, but 5 there's two Maxes, I think, that I've worked 6 with in this case, but...</p> <p>7 Q. Do you know what his background 8 is?</p> <p>9 A. I believe an undergraduate 10 degree, probably in economics or mathematics 11 or statistics.</p> <p>12 Q. Do you know from where?</p> <p>13 A. I don't know from where, no.</p> <p>14 Q. What was his role?</p> <p>15 A. He had -- he would have had a 16 similar role as Ms. Kim. In general, as you 17 go through the invoices, the analysts and 18 senior analysts all have quite similar roles, 19 analyzing data, culling through documents, 20 synthesizing information, all under my 21 direction.</p> <p>22 Q. Let's go to -- a new name shows 23 up in the July 27, 2018 invoice. Tell me 24 when you're there. Page 3 of that invoice.</p>
<p style="text-align: center;">Page 123</p> <p>1 able to do that?</p> <p>2 A. I was able to replicate quite 3 closely his analysis. There's actually some 4 issues in his analysis that I mention in the 5 report.</p> <p>6 For example, in one of his 7 methodologies, which is a methodology for 8 comparing the current pharmacy distribution 9 to an average in the last several months, his 10 methodology states that he uses the averages 11 nationally. In fact, there's a coding error 12 that I and my team uncovered. He actually 13 only used the averages in the state -- the 14 counties at issue here, Cuyahoga and Summit.</p> <p>15 So, for the most part, I would 16 say that I was able to replicate his 17 analysis. That's not a -- that's not a 18 statement of whether I think his analysis is 19 valid. It could be replicated somewhat. But 20 it's a separate issue of whether I think that 21 analysis is correct. And I go to great 22 lengths in the report to say that I don't 23 think it is.</p> <p>24 Q. Okay. Mr. Flignor -- did I say</p>	<p style="text-align: center;">Page 125</p> <p>1 A. Yes.</p> <p>2 Q. Okay. Again, we can 3 cross-check your time with Exhibit 2. You 4 billed 11 hours in June. Does that match up 5 with your time in June on your time from 6 Exhibit 2?</p> <p>7 A. That does match up, yes.</p> <p>8 Q. Okay. So the last name is 9 Briesemeister?</p> <p>10 A. Briesemeister.</p> <p>11 Q. Briesemeister.</p> <p>12 A. Joe.</p> <p>13 Q. Joe.</p> <p>14 What does Joe do?</p> <p>15 A. Joe has a very similar role to 16 both Soojin and Mr. Flignor as an analyst or 17 senior analyst, in this case he's an analyst, 18 same types of tasks I just outlined.</p> <p>19 Q. Do you know what his background 20 is?</p> <p>21 A. I believe also an undergraduate 22 degree.</p> <p>23 Q. You don't know in what?</p> <p>24 A. I think either economics or</p>

Page 126	Page 128
<p>1 statistics. Most of the analysts and senior 2 analysts at Analysis Group and other similar 3 firms have an undergraduate degree in 4 economics or statistics.</p> <p>5 Q. If you go about halfway 6 through, the December 21, 2018 invoice -- 7 tell me when you're there.</p> <p>8 A. I'm there.</p> <p>9 Q. Okay. Then go to Page 2.</p> <p>10 We see Erica VanSant's name?</p> <p>11 A. Yes.</p> <p>12 Q. You mentioned her earlier?</p> <p>13 A. Yes.</p> <p>14 Q. What was her role?</p> <p>15 A. She's an associate in Analysis 16 Group. She has a PhD in economics from 17 Carnegie Mellon University. She had a very 18 similar role as Stephen Fink, overseeing some 19 of the senior analysts and analysts that were 20 involved in those tasks that I outlined.</p> <p>21 Q. Okay. So she was overseeing 22 some of the other analysts?</p> <p>23 A. That's correct, along with 24 Mr. Fink.</p>	<p>1 is my report. I edited it heavily. The 2 language that you see there, that's my 3 language.</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. Go to the April 29, 2019 6 invoice. Go to Page 3. Tell me when you're 7 there.</p> <p>8 A. I'm there.</p> <p>9 Q. All right. So then we see some 10 additional names show up here.</p> <p>11 M. Lewis. Is that Max Lewis?</p> <p>12 A. Mark Lewis.</p> <p>13 Q. Okay. What does Mark Lewis do?</p> <p>14 A. Mark is a vice president at 15 Analysis Group. He has a background in 16 economics. He's been an economic litigation 17 consultant for many years. He was involved 18 in helping Ms. Fink -- Mr. Fink and 19 Ms. VanSant.</p> <p>20 Q. For what specifically was he 21 doing helping them?</p> <p>22 A. Also similar project oversight.</p> <p>23 This is a period -- as you can see, 24 March 31st, my own time now becomes more</p>
<p style="text-align: center;">Page 127</p> <p>1 Q. She had more involvement in 2 your report than some of the other people? 3 You brought her with you to the meetings?</p> <p>4 MS. MCENROE: Objection to 5 form.</p> <p>6 A. She has had a role in my report 7 as a leadership role within Analysis Group, 8 along with Mr. Fink.</p> <p>9 BY MR. PIFKO:</p> <p>10 Q. Did she draft some portions of 11 the report as well?</p> <p>12 MS. MCENROE: Objection to 13 form.</p> <p>14 A. The report as you see it is my 15 report. I drafted a large part of it. There 16 are certain portions which I thought were 17 fairly straightforward for someone who 18 doesn't need to have a PhD and MD to draft. 19 And so for those portions, Mr. Fink, 20 Ms. VanSant would probably have been doing 21 some of the drafting. It's possible that 22 some of the other analysts would have also 23 been doing the drafting.</p> <p>24 But at the end of the day, this</p>	<p style="text-align: center;">Page 129</p> <p>1 considerable. This is the part of the 2 invoices where I'm starting to work in 3 earnest on the report.</p> <p>4 And now you can see that the 5 team has increased in size to make sure that 6 all the different analyses that I'm 7 suggesting are getting done in a timely way, 8 can be ready to be prepared by the May 10th 9 filing.</p> <p>10 Q. Do you know if Mr. Lewis 11 drafted any portions of the report?</p> <p>12 MS. MCENROE: Objection to 13 form.</p> <p>14 A. Mr. Lewis, Mr. Fink, and 15 Ms. VanSant would have been involved under my 16 direction at portions of drafting.</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. We see another name, 19 D. Kellachan.</p> <p>20 A. Dylan.</p> <p>21 Q. Dylan?</p> <p>22 A. D-Y-L-A-N.</p> <p>23 Q. Is that a woman?</p> <p>24 A. That's a man.</p>

Page 130	Page 132
<p>1 Q. Okay. What's his background?</p> <p>2 A. He also has a background in</p> <p>3 economics, I believe a master's degree, and</p> <p>4 also experienced in litigation economic work.</p> <p>5 Q. And what was his role?</p> <p>6 A. Same type of role as Erica</p> <p>7 VanSant.</p> <p>8 Q. A management oversight role?</p> <p>9 A. Management, yeah. I mean,</p> <p>10 they -- I would describe it in the following;</p> <p>11 senior analysts and analysts are doing much</p> <p>12 more of the data analysis and data</p> <p>13 processing. Associates and vice-presidents</p> <p>14 have a similar role. There is management of</p> <p>15 the analysts, but they're also involved in</p> <p>16 double checking, and then in my case also</p> <p>17 triple checking.</p> <p>18 The idea here is this report</p> <p>19 has got to be thorough, it's got to be done</p> <p>20 in a way that meets the academic standards</p> <p>21 that I have. I'm signing my name to it, and</p> <p>22 so I want to make sure each one of these</p> <p>23 people is doing exactly what I tell them to</p> <p>24 do -- ask them to do for the report.</p>	<p>1 documents that are publicly available, and,</p> <p>2 of course, my experience as a physician, as a</p> <p>3 health policy researcher, as an economist,</p> <p>4 those comprise the opinion.</p> <p>5 Q. Did you consider anything else</p> <p>6 outside of what you just said and what's in</p> <p>7 your report in forming your opinions?</p> <p>8 MS. MCENROE: Objection to</p> <p>9 form.</p> <p>10 A. No.</p> <p>11 BY MR. PIFKO:</p> <p>12 Q. Is Exhibit 4 a true and correct</p> <p>13 copy of your report?</p> <p>14 MS. MCENROE: Objection to</p> <p>15 form.</p> <p>16 Do you want him to go through</p> <p>17 page by page?</p> <p>18 A. Exhibit 4 appears to be a true</p> <p>19 and accurate reflection of my report.</p> <p>20 BY MR. PIFKO:</p> <p>21 Q. Okay. Does Exhibit 4 reflect</p> <p>22 all the opinions that you intend to provide</p> <p>23 in this case?</p> <p>24 MS. MCENROE: Objection to</p>
<p style="text-align: center;">Page 131</p> <p>1 (Whereupon, Jena Exhibit Number</p> <p>2 4 was marked for identification.)</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. I'm handing you what's marked</p> <p>5 as Exhibit 4.</p> <p>6 A. Thank you.</p> <p>7 Q. Take a moment to review that.</p> <p>8 Let me know when you're done.</p> <p>9 A. This is my report.</p> <p>10 Q. All right. First question, can</p> <p>11 you tell me what Exhibit 4 is?</p> <p>12 A. Exhibit 4 is my report.</p> <p>13 Q. Okay. And to be clear, it's --</p> <p>14 the appendices are not included as part of</p> <p>15 Exhibit 4.</p> <p>16 Other than the appendices, does</p> <p>17 Exhibit 4 reflect all the work that you did</p> <p>18 in forming your opinions in this case?</p> <p>19 MS. MCENROE: Objection to</p> <p>20 form.</p> <p>21 A. Exhibit 4 reflects my opinions.</p> <p>22 The materials that I considered in the report</p> <p>23 are listed in the appendix. That includes</p> <p>24 documents produced in litigation, outside</p>	<p style="text-align: center;">Page 133</p> <p>1 form.</p> <p>2 A. Exhibit 4 reflects the opinions</p> <p>3 that I provided to date. I reserve the right</p> <p>4 to provide additional opinions should</p> <p>5 additional information surface, or if I'm</p> <p>6 asked by counsel to opine on other issues.</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. Do you intend to perform</p> <p>9 additional work after this deposition --</p> <p>10 MS. MCENROE: Objection to</p> <p>11 form.</p> <p>12 BY MR. PIFKO:</p> <p>13 Q. -- on this case?</p> <p>14 A. I have no plan or intention to</p> <p>15 perform additional work on this case. If I'm</p> <p>16 asked to do so, I may choose to do so. But</p> <p>17 as of now, I have no firm intention of doing</p> <p>18 that.</p> <p>19 Q. Has counsel asked you to do any</p> <p>20 additional work on the case in connection</p> <p>21 with your report?</p> <p>22 MS. MCENROE: Objection to</p> <p>23 form.</p> <p>24 A. No further work has been</p>

Page 134	Page 136
<p>1 requested of me for this case.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. Is there anything that's</p> <p>4 missing or incomplete from your report that</p> <p>5 you need to finish after -- as of this date?</p> <p>6 A. No. This report is complete as</p> <p>7 you have it.</p> <p>8 Q. Can you summarize your opinions</p> <p>9 for me?</p> <p>10 A. Sure.</p> <p>11 So let me point you to the</p> <p>12 right page so you can see where I'm going to</p> <p>13 be talking to you from. So if you start at</p> <p>14 Page 4, it outlines the beginning of the</p> <p>15 Summary of Conclusions.</p> <p>16 So basically there's four main</p> <p>17 conclusions.</p> <p>18 The first conclusion is that</p> <p>19 Rite Aid, Mid-Atlantic as a distributor, in</p> <p>20 my opinion, had in place effective</p> <p>21 anti-diversion measures as a distributor.</p> <p>22 That's the first opinion.</p> <p>23 The second is, if you look at</p> <p>24 Dr. McCann's methodology, my view is this is</p>	<p>1 section of my report that goes through that</p> <p>2 in more detail.</p> <p>3 Q. Did Rite Aid's counsel draft</p> <p>4 any portions of the report?</p> <p>5 MS. MCENROE: Objection to</p> <p>6 form.</p> <p>7 And I instruct you, in terms of</p> <p>8 substantive discussions with counsel,</p> <p>9 that is privileged, and you should not</p> <p>10 respond.</p> <p>11 In terms of mechanics of your</p> <p>12 report, I'm not trying to stop you</p> <p>13 from responding, but I recognize that</p> <p>14 there's a fine line there, so I ask</p> <p>15 you not to divulge privileged</p> <p>16 information.</p> <p>17 A. This is my report. I and my</p> <p>18 team drafted it, not the counsel.</p> <p>19 BY MR. PIFKO:</p> <p>20 Q. So they had no involvement in</p> <p>21 drafting it? Is that your testimony, just to</p> <p>22 be clear?</p> <p>23 MS. MCENROE: Objection to</p> <p>24 form.</p>
Page 135	Page 137
<p>1 a methodology for identifying suspicious</p> <p>2 orders, the methodology is flawed. And I'm</p> <p>3 happy to walk through why it is the case if</p> <p>4 you'd like.</p> <p>5 Third is from the perspective</p> <p>6 of whether or not there's any harm caused by</p> <p>7 diversion of opioids from Rite Aid</p> <p>8 pharmacies. I find no evidence of any harm</p> <p>9 arising from diversion of opioids from Rite</p> <p>10 Aid pharmacies.</p> <p>11 And the fourth is that -- is an</p> <p>12 important point, that the plaintiffs'</p> <p>13 experts' reports don't characterize</p> <p>14 Rite Aid's role as a distributor in the way</p> <p>15 that I think that we should be characterizing</p> <p>16 distributors and separating the role of</p> <p>17 distributors from pharmacists, from</p> <p>18 physicians. And the interplay of the opioid</p> <p>19 epidemic that we're in right now is a</p> <p>20 complicated one, and it relies on many</p> <p>21 different factors.</p> <p>22 And the last part of my opinion</p> <p>23 is that we cannot ignore the role of</p> <p>24 prescribers in the epidemic. And there's a</p>	<p>1 A. Counsel has reviewed the report</p> <p>2 but did not write sentences or tell me to say</p> <p>3 one thing or the other.</p> <p>4 Just to be very clear, the</p> <p>5 opinions in this report, these are my</p> <p>6 opinions. The direction that the report</p> <p>7 took, that was my direction.</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. You said that if you became</p> <p>10 aware of additional information, you maybe</p> <p>11 would revisit your opinions. Did I hear you</p> <p>12 correctly?</p> <p>13 MS. MCENROE: Objection to</p> <p>14 form.</p> <p>15 A. If there's any information that</p> <p>16 is brought to my attention that contradicts</p> <p>17 portions of my report, I suppose that I'd be</p> <p>18 willing to look at that and consider that. I</p> <p>19 have no intention at all of being involved in</p> <p>20 this case any further beyond this. If I'm</p> <p>21 asked to do something, an assignment, I will</p> <p>22 consider it at that time. But right now,</p> <p>23 what you have in front of you, this report,</p> <p>24 is my plan.</p>

Page 138	Page 140
<p>1 BY MR. PIFKO:</p> <p>2 Q. All my question was going to be 3 was, if you were aware of any information 4 that potentially contradicts your report that 5 you intend to look at?</p> <p>6 A. Oh, absolutely not. I'm not 7 aware of any such information.</p> <p>8 Q. Do you intend to provide any -- 9 do you intend to testify at trial if there's 10 a trial in this case?</p> <p>11 A. If I'm asked to testify at 12 trial, then I suspect I would be able and 13 willing to testify at trial.</p> <p>14 Q. Okay. And Exhibit 4 reflects a 15 complete set of the opinions that you would 16 provide at trial, correct?</p> <p>17 MS. MCENROE: Objection to 18 form.</p> <p>19 A. This provides my opinions to 20 date. If any new information is produced 21 from now until then, I would reserve the 22 right to analyze an opinion and give my 23 unbiased opinion.</p> <p>24 BY MR. PIFKO:</p>	<p>1 opinion, might be useful to illustrate the 2 opinions in my report.</p> <p>3 BY MR. PIFKO:</p> <p>4 Q. Let's look at some of the 5 appendices that you provided.</p> <p>6 (Whereupon, Jena Exhibit Number 7 5 was marked for identification.)</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Handing you what's marked as 10 Exhibit 5.</p> <p>11 A. Thanks.</p> <p>12 Q. Take a minute to look at 13 Exhibit 5, and let me know when you're done.</p> <p>14 A. I'm done.</p> <p>15 Q. Okay. Can you tell me what 16 Exhibit 5 is?</p> <p>17 A. Sure. So Exhibit 5 reflects an 18 analysis that I conducted which is called a 19 falsification analysis. The idea behind a 20 falsification analysis -- and I have a paper 21 published on this in the Journal of Medical 22 Research, which is MICV.</p> <p>23 The basic idea behind the 24 falsification analysis is to see whether some</p>
<p>1 Q. But other than new information 2 that doesn't exist as of today, Exhibit 4 3 represents the opinions that you would 4 provide at trial, correct?</p> <p>5 A. That is --</p> <p>6 MS. MCENROE: Objection to 7 form.</p> <p>8 A. I apologize.</p> <p>9 That is correct.</p> <p>10 BY MR. PIFKO:</p> <p>11 Q. Other than the people at 12 Analysis Group that we discussed, did you 13 talk to anyone else about your report?</p> <p>14 A. No.</p> <p>15 Q. Did you talk about your report 16 or your opinions with any other academic 17 colleagues?</p> <p>18 A. No.</p> <p>19 Q. If you testify at trial, do you 20 intend to provide any demonstrative exhibits?</p> <p>21 MS. MCENROE: Objection to 22 form.</p> <p>23 A. I would reserve the right to do 24 that. Probably some of the exhibits, in my</p>	<p>1 of the patterns that Dr. McCann outlined as 2 being -- as flagging -- let me use the word 3 "potentially suspicious" because other 4 plaintiffs' experts used the report in that 5 way.</p> <p>6 The question is whether or not 7 the methodology that he uses for flagging 8 orders is legitimate. One sign that the 9 analysis would not be legitimate or valid 10 scientifically is, if you can generate the 11 same sorts of patterns using drugs that are 12 not addictive, that don't cause harm in the 13 way that opioids do, and that have no street 14 value.</p> <p>15 So if you're able to generate 16 the same findings with non-opioid drugs, that 17 should raise a red flag as to whether or not 18 the primary methodology that you're using, in 19 this case Dr. McCann, is valid. So Appendix 20 E presents 80 plots that are basically 21 store-by-store analyses of figures that are 22 in the report.</p> <p>23 And in the report, what I 24 basically show is that the patterns that</p>

<p style="text-align: right;">Page 142</p> <p>1 Dr. McCann shows with opioids, that he and 2 then other plaintiffs' experts suggest is 3 illustrative of suspicious ordering, 4 suspicious distribution, those same patterns 5 occur when you look at drugs like 6 levothyroxine, that's a very common thyroid 7 medication, metoprolol succinate, that's a 8 beta blocker medication for heart disease, 9 statins, cholesterol medications, amlodipine, 10 which is a calcium channel blocker to treat 11 hypertension, you see the exact same patterns 12 with these other drugs as you see with 13 opioids.</p> <p>14 So that to me is strong 15 evidence that whatever Dr. McCann is doing 16 when he's trying to, quote/unquote, flag 17 orders in opioids one could very easily 18 replicate with other very standard drugs.</p> <p>19 And, by the way, these drugs 20 are very standard. I chose these drugs 21 because during this period, I think in 2006, 22 they are the top three or four selling drugs 23 in the market at the time. So these aren't 24 cherry-picked in any way. Appendix E</p>	<p style="text-align: right;">Page 144</p> <p>1 Q. Okay. Are there any 2 falsification tests that you performed on 3 other products that you didn't end up 4 including in your report?</p> <p>5 A. No. These were the products 6 that were analyzed. The reason I chose them 7 is because they were the top-selling drugs in 8 the period at issue.</p> <p>9 Q. Did you perform any other 10 analysis of data that you didn't include in 11 your report?</p> <p>12 MS. MCENROE: Objection to 13 form.</p> <p>14 A. All the analysis of data that I 15 performed is in this report. (Whereupon, Jena Exhibit Number 16 6 was marked for identification.)</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. Handing you what's marked as 19 Exhibit 6.</p> <p>20 A. Thank you.</p> <p>21 MS. MCENROE: Thank you.</p> <p>22 BY MR. PIFKO:</p> <p>23 Q. Take a minute to review that,</p>
<p style="text-align: right;">Page 143</p> <p>1 basically takes the plots that are in the 2 report and does it store by store.</p> <p>3 That's a long-winded way to 4 describe what Appendix E is.</p> <p>5 Q. Okay. And did someone at 6 Analysis Group actually prepare these charts?</p> <p>7 A. Someone at Analysis Group 8 prepared these charts under my direction.</p> <p>9 And this was my idea, by the way. I publish 10 on falsification tests, and so I said to the 11 team, we've got to show this. In order to 12 say that this methodology is not robust, 13 meaning Dr. McCann's methodology, I want to 14 be able to take the best academic evidence 15 that there is and the best academic 16 approaches and look at it in this way. And 17 this is just a very transparent way -- it's a 18 lengthy way, but it's a transparent way to 19 show that.</p> <p>20 Q. Are there any -- did you say 21 falsification tests? Is that what they're 22 called?</p> <p>23 A. That's what they're called, 24 yes.</p>	<p style="text-align: right;">Page 145</p> <p>1 and let me know when you're done.</p> <p>2 A. Okay. I'm done.</p> <p>3 Q. Can you tell me what Exhibit 6 4 is?</p> <p>5 A. Sure. Exhibit 6 reflects 6 Appendix D, which is an appendix in my report 7 which I just very briefly summarize 8 plaintiffs' experts' reports mentioning Rite 9 Aid.</p> <p>10 Q. And what does Exhibit 6 tell me 11 about other reports?</p> <p>12 MS. MCENROE: Objection to 13 form.</p> <p>14 A. It does two things. First, it 15 just gives you a very high-level summary of 16 the expert assignment or opinion in each one 17 of the reports. That's the third column. 18 And then it identifies whether or not Rite 19 Aid was mentioned in the report, either 20 identified as a defendant, which is the 21 third-to-last column, or included in the 22 materials considered, which is the 23 second-to-last column.</p> <p>24 BY MR. PIFKO:</p>

Page 146	Page 148
<p>1 Q. Did you prepare Exhibit 6?</p> <p>2 A. I asked the team to prepare</p> <p>3 Exhibit 6 according to my guidelines.</p> <p>4 Q. Okay. So someone at Analysis</p> <p>5 Group prepared Exhibit 6?</p> <p>6 MS. MCENROE: Objection to</p> <p>7 form.</p> <p>8 A. Someone at Analysis Group</p> <p>9 prepared Exhibit 6 under my guidelines. I</p> <p>10 like -- this is my report, so I don't want to</p> <p>11 say that someone else is -- I don't want to</p> <p>12 give credit to someone else for what is my</p> <p>13 report. Someone assisted me in developing</p> <p>14 Appendix B, which is Exhibit 6.</p> <p>15 BY MR. PIFKO:</p> <p>16 Q. Do you know who specifically at</p> <p>17 Analysis Group put the information into</p> <p>18 Exhibit 6?</p> <p>19 A. So Mr. Fink, Ms. VanSant would</p> <p>20 definitely have been involved, and one or two</p> <p>21 of the other analysts.</p> <p>22 The reason why is because there</p> <p>23 are multiple different reports that are</p> <p>24 culled through.</p>	<p>1 form.</p> <p>2 A. The -- I suspect that the</p> <p>3 versions that are reported here are the</p> <p>4 initial versions that were performed. As you</p> <p>5 can see here, the table is illustrating a few</p> <p>6 things, not a lot. What's the expert</p> <p>7 assignment? So to the extent that the</p> <p>8 assignment would have changed in an</p> <p>9 amendment, which I don't think it would have,</p> <p>10 that's a non-issue. The core opinion would</p> <p>11 have changed? I don't think it would have.</p> <p>12 That would be a non-issue. And whether Rite</p> <p>13 Aid was mentioned, I'm not aware of any</p> <p>14 changes in reports that now mention Rite Aid</p> <p>15 that had not previously mentioned Rite Aid.</p> <p>16 BY MR. PIFKO:</p> <p>17 Q. Okay. But you don't know</p> <p>18 either way whether the team reviewed any</p> <p>19 amendments?</p> <p>20 MS. MCENROE: Objection to</p> <p>21 form.</p> <p>22 A. I don't know whether or not the</p> <p>23 team reviewed amendments. But I -- if they</p> <p>24 were available, I would suspect so, but I</p>
<p>1 Q. All right. So this has numbers</p> <p>2 on the left for each expert, correct?</p> <p>3 A. That is correct.</p> <p>4 Q. Do you know if -- there's 21 of</p> <p>5 them. Do you agree?</p> <p>6 A. I agree.</p> <p>7 Q. Do you know if all these</p> <p>8 experts provided a report?</p> <p>9 A. So from the exhibit it appears</p> <p>10 that all the experts provided a report. I'm</p> <p>11 not sure if all those reports have ultimately</p> <p>12 made it into the litigation. I understand</p> <p>13 that at various stages there were experts</p> <p>14 whose reports did not make it into the</p> <p>15 subsequent litigation. I don't know the</p> <p>16 legalese around it. But these are the</p> <p>17 reports that my team reviewed.</p> <p>18 Q. Okay. Do you know if there are</p> <p>19 any amendments to any of these reports?</p> <p>20 A. I am not aware of whether or</p> <p>21 not amendments were filed to these reports.</p> <p>22 Q. If there were amendments, do</p> <p>23 you know what version the team reviewed?</p> <p>24 MS. MCENROE: Objection to</p>	<p>1 Page 147</p> <p>1 cannot tell you for sure.</p> <p>2 BY MR. PIFKO:</p> <p>3 Q. Did you review all 21 of these</p> <p>4 reports?</p> <p>5 A. I reviewed in detail several of</p> <p>6 the reports, particularly ones that I had</p> <p>7 drawn in my -- in my own report. Some of the</p> <p>8 reports are not -- are somewhat orthogonal to</p> <p>9 what I'm talking about here, and so I didn't</p> <p>10 review those in detail.</p> <p>11 And I asked my team to go</p> <p>12 through the reports and identify whether or</p> <p>13 not there's any issues that I should be aware</p> <p>14 of as they relate to my assignment and as</p> <p>15 they relate to the core opinions that I</p> <p>16 wanted to make here.</p> <p>17 Q. Okay. So is your testimony</p> <p>18 that you reviewed all the reports to some</p> <p>19 degree?</p> <p>20 MS. MCENROE: Objection to</p> <p>21 form.</p> <p>22 A. My testimony would be that I</p> <p>23 reviewed all reports to some degree, but with</p> <p>24 much greater degree to the reports that are</p>

Page 150	Page 152
<p>1 germane to mine.</p> <p>2 For example, McCann's report I</p> <p>3 read page to page multiple times because I</p> <p>4 spent half of my report talking about his own</p> <p>5 report.</p> <p>6 BY MR. PIFKO:</p> <p>7 Q. Okay. And let's just go</p> <p>8 through them.</p> <p>9 David Courtwright's report, did</p> <p>10 you read that cover to cover?</p> <p>11 A. No. The only report that I</p> <p>12 would have read cover to cover would be</p> <p>13 Mr. McCann's report.</p> <p>14 Q. Okay. So you didn't --</p> <p>15 A. And possibly Mr. -- Professor</p> <p>16 Cutler's report as well, though that was a</p> <p>17 little bit further back, and I only allude to</p> <p>18 it very briefly in my own report.</p> <p>19 Q. You said possibly David</p> <p>20 Cutler's report. Did you -- do you know one</p> <p>21 way or another if you reviewed it cover to</p> <p>22 cover?</p> <p>23 A. I reviewed the majority of</p> <p>24 Mr. Cutler's report, and I reviewed the</p>	<p>1 A. No. So I can -- the</p> <p>2 individuals -- several of these individuals</p> <p>3 are at Harvard and MIT, so one of them is a</p> <p>4 collaborator of mine on some work.</p> <p>5 Q. Who is that?</p> <p>6 A. That's Professor Gruber. We've</p> <p>7 collaborated on projects. I wasn't aware</p> <p>8 that he was involved in the opioid litigation</p> <p>9 until an expert report was filed.</p> <p>10 David Cutler is a professor at</p> <p>11 Harvard.</p> <p>12 Thomas McGuire is a professor</p> <p>13 at Harvard.</p> <p>14 And Meredith Rosenthal is a</p> <p>15 professor at Harvard.</p> <p>16 If I were to look back in my</p> <p>17 social calendar in the last six months to a</p> <p>18 year, I don't think I've had dinner with any</p> <p>19 of these individuals. That would be one</p> <p>20 proxy for your question.</p> <p>21 Q. Caleb Alexander, you said you</p> <p>22 know him professionally. How do you know</p> <p>23 him?</p> <p>24 A. I know him in a limited way. I</p>
Page 151	Page 153
<p>1 entirety of Mr. McCann's report, and I</p> <p>2 directed my team to review in detail each one</p> <p>3 of these reports.</p> <p>4 Q. So we have this list of these</p> <p>5 21 names. Do you know any of these</p> <p>6 individuals professionally or personally?</p> <p>7 A. Some of these individuals I</p> <p>8 would know professionally.</p> <p>9 Q. Okay. Which ones do you know</p> <p>10 professionally?</p> <p>11 A. So Number 3, Professor Caleb</p> <p>12 Alexander; 4, Professor Cutler; 6,</p> <p>13 Professor Gruber; 11, Professor McGuire; 13,</p> <p>14 Professor Rosenthal. And I believe that's</p> <p>15 it.</p> <p>16 Q. Okay. Do you know any of these</p> <p>17 people personally?</p> <p>18 A. What do you mean by</p> <p>19 "personally"?</p> <p>20 Q. Well, like you know someone in</p> <p>21 a professional capacity, maybe you interact</p> <p>22 with them in a working manner, but maybe some</p> <p>23 people you know them socially is what I'm</p> <p>24 asking.</p>	<p>1 think we had some overlap at the University</p> <p>2 of Chicago. He's now at Johns Hopkins, and</p> <p>3 he's been there many years. I probably saw</p> <p>4 him last maybe six years ago, five or six</p> <p>5 years.</p> <p>6 Q. We talked about David Cutler.</p> <p>7 You know him from Harvard?</p> <p>8 A. Yes.</p> <p>9 Q. Jonathan Gruber?</p> <p>10 A. From MIT.</p> <p>11 Q. You know him from when you were</p> <p>12 an undergrad there?</p> <p>13 A. No. I do not know him from</p> <p>14 undergrad. I don't know if he was there when</p> <p>15 I was an undergrad. He may not -- that was a</p> <p>16 long time ago.</p> <p>17 Q. Yeah. So that's what I was</p> <p>18 just clarifying for the record.</p> <p>19 So you know him because you --</p> <p>20 because you're both in Boston, you interact</p> <p>21 with him?</p> <p>22 A. Exactly. These are all very</p> <p>23 good health economists.</p> <p>24 Q. Thomas McGuire?</p>

Page 154	Page 156
<p>1 A. Also at Harvard.</p> <p>2 Q. And Meredith Rosenthal, same</p> <p>3 thing?</p> <p>4 A. Yes, also Harvard.</p> <p>5 (Whereupon, Jena Exhibit</p> <p>6 Number 7 was marked for</p> <p>7 identification.)</p> <p>8 BY MR. PIFKO:</p> <p>9 Q. Handing you what's marked as</p> <p>10 Exhibit 7. Take a minute to look at</p> <p>11 Exhibit 7. Let me know when you're done.</p> <p>12 A. I'm done.</p> <p>13 Q. Okay. Can you tell me what</p> <p>14 Exhibit 7 is?</p> <p>15 A. Sure. Exhibit 7 is Appendix C</p> <p>16 in my report. It reports Materials</p> <p>17 Considered.</p> <p>18 Q. This is a true and correct copy</p> <p>19 of all the materials considered?</p> <p>20 A. I believe so.</p> <p>21 Q. To your knowledge, there's</p> <p>22 nothing that you considered that's not in</p> <p>23 here?</p> <p>24 A. That's correct.</p>	<p>1 facility, as well as the headquarter, had in</p> <p>2 place to prevent the diversion of opioids.</p> <p>3 Q. And that's how this list was</p> <p>4 created?</p> <p>5 A. That is correct.</p> <p>6 Q. Do you know how the team</p> <p>7 obtained access to the documents?</p> <p>8 A. They had access to all the</p> <p>9 documents that have been produced in the</p> <p>10 litigation.</p> <p>11 Q. Okay. Do you know physically</p> <p>12 how they had that access?</p> <p>13 A. "Physically," can you clarify</p> <p>14 what you mean?</p> <p>15 Q. How did they gain access to all</p> <p>16 the documents in the litigation?</p> <p>17 A. How -- do you mean by computer</p> <p>18 or what --</p> <p>19 Q. Whatever --</p> <p>20 A. -- legal authority gave them</p> <p>21 that?</p> <p>22 Q. Whatever method they used.</p> <p>23 A. Oh, I would assume that most of</p> <p>24 it is electronic, and maybe through servers,</p>
<p>1 Q. To your knowledge, is there</p> <p>2 anything that you didn't consider that's in</p> <p>3 here?</p> <p>4 A. No.</p> <p>5 Q. Partway through we have -- if</p> <p>6 you'd go to C-5. So C-5 through C-11 makes</p> <p>7 reference to documents in the litigation.</p> <p>8 A. Yes.</p> <p>9 Q. Let me know when you're there.</p> <p>10 A. I'm there.</p> <p>11 Q. Okay. How did you come to</p> <p>12 obtain these specific documents?</p> <p>13 A. My team had full access to the</p> <p>14 documents that are produced in litigation,</p> <p>15 again, as well as my other research and</p> <p>16 publicly available documents. And in forming</p> <p>17 my outline and in devising a strategy to</p> <p>18 thinking about the quality of anti-diversion</p> <p>19 at Rite Aid, as well as other related issues,</p> <p>20 I asked my team to search through documents</p> <p>21 specifically within Rite Aid, but also other</p> <p>22 places, to document exactly what are the</p> <p>23 different processes and structures that the</p> <p>24 organization, Mid-Atlantic distribution</p>	<p>1 maybe through disks. I'm not sure in each</p> <p>2 one of these cases how the specific document</p> <p>3 was obtained.</p> <p>4 Q. Okay. Did you personally</p> <p>5 review any of these documents?</p> <p>6 A. Yes, I have reviewed some of</p> <p>7 these documents.</p> <p>8 Q. Do you know which ones?</p> <p>9 A. If we went through my report,</p> <p>10 the specific documents that I call on in the</p> <p>11 report itself as opposed to in the materials</p> <p>12 considered, each one of those documents I</p> <p>13 would have -- I would have reviewed</p> <p>14 personally, as well as other documents that</p> <p>15 are in the materials considered that I may</p> <p>16 not have cited in the actual report itself.</p> <p>17 Q. How did you come to access the</p> <p>18 documents?</p> <p>19 A. I would access them through a</p> <p>20 computer provided to me as a PDF file.</p> <p>21 Q. Okay. So the team would send</p> <p>22 you a PDF of certain documents?</p> <p>23 A. That's correct.</p> <p>24 Q. Via e-mail or something?</p>

Page 158	Page 160
<p>1 A. Not via e-mail. Usually 2 through a secure mechanism. 3 Q. Okay. Like an FTP exchange? 4 A. Something like that. 5 Q. So from time to time the team 6 would upload some documents for your 7 attention? Is that how it works? 8 A. From time to time they would do 9 that. And also in my report I have a zip 10 file, which is a compressed data file that's 11 probably more than 1 gigabyte, which links to 12 the exact documents that I rely on in my 13 report. 14 So, for instance, if I make a 15 comment and I want to refresh my memory, look 16 at what the underlying document is, I can 17 click on that link in my report, it takes me 18 to the underlying document and I can look at 19 the entire document so I can understand where 20 my particular statement in the report sits 21 and fits into the overall context of the 22 underlying document. 23 Q. So you have an electronic 24 version that's hyperlinked, basically, is</p>	<p>1 reviewed? 2 A. Sure. I can estimate. If we 3 want to do it in a thorough way, we'd have to 4 spend quite a bit of time with the report, 5 but Debra Chase, Keith Frost, Larry Ringgold, 6 Marian Wood, Janet Getzey Hart, Kyle Wright, 7 Thomas Prevoznik, Joseph Rannazzisi, Matthew 8 Perri. These are the ones that are 9 immediately coming to mind -- to my mind. 10 Q. Did you read those cover to 11 cover? 12 A. I did not read each one of 13 these depositions cover to cover, but I read 14 the portions that are relevant to my opinion, 15 because these are broad -- many of these are 16 broad fact depositions, and I read the 17 portions that are critical to my opinion. 18 Q. How did you determine which 19 portions were relevant to your opinion? 20 A. I directed my team to read 21 through the reports, in this case the 22 depositions, and asked them to identify the 23 places in the report where arguments or facts 24 were being stated that were critical to my</p>
<p style="text-align: center;">Page 159</p> <p>1 that what you're saying? 2 A. To -- not to the entire 3 materials considered, but to the things that 4 are cited in the report. 5 Q. Okay. So if something is cited 6 in the report, you can click on it, and then 7 it pulls up the actual document, is that what 8 you're saying? 9 A. That's correct. 10 Q. How about deposition 11 transcripts, did you personally review any 12 deposition transcripts? 13 A. I did. 14 Q. Do you know which ones? 15 A. I can look at them in the 16 report, but, in particular, Section 4 17 outlines a lot of deposition transcripts from 18 various Rite Aid employees, DEA employees, 19 Maryland State Board of Pharmacy documents. 20 So those are the places in the report where I 21 rely most heavily on deposition testimony. 22 Q. Looking at Exhibit 7, the first 23 page, it's got depositions. Can you tell me 24 which depositions that you personally</p>	<p style="text-align: center;">Page 161</p> <p>1 understanding of what are the structures and 2 processes that Rite Aid has in place to 3 prevent diversion of opioids. 4 Q. Go to Page C-4. Let me know 5 when you're there. 6 A. I'm there. 7 Q. Okay. See the section "Other 8 Court Documents"? 9 A. Yes. 10 Q. It's got -- the first two items 11 are legal citations. Do you know what those 12 are? 13 A. I believe one of them refers to 14 the Controlled Substances Act. I'd have to 15 flip through my report for the other one. 16 Unfortunately, I'm not a legal 17 scholar, so I don't even know what that 18 little squiggly sign means. 19 Q. Did you read the first one in 20 its entirety? 21 A. So I believe that that refers 22 to portions of the Controlled Substances Act. 23 I haven't read the document in its entirety, 24 but I did read the portions that are relevant</p>

Page 162	Page 164
<p>1 to my report.</p> <p>2 Q. Okay.</p> <p>3 A. And I'm also not a legal</p> <p>4 scholar, so my ability to interpret it in a</p> <p>5 legal way would be, not just limited, it</p> <p>6 would be zero.</p> <p>7 Q. Okay. And then my question is</p> <p>8 how do you -- how did you determine which</p> <p>9 portions were relevant to your report?</p> <p>10 A. It's very clear, actually,</p> <p>11 because I wanted to look at two things. One</p> <p>12 is what does the Act state with respect to</p> <p>13 the level of effective control that a</p> <p>14 distributor should have under the CSA; and</p> <p>15 then, secondly, what should be the</p> <p>16 expectations required to the monitoring and</p> <p>17 evaluation of orders that might be of</p> <p>18 potentially unusual size or frequency or</p> <p>19 pattern.</p> <p>20 Q. Okay. How specifically did you</p> <p>21 determine which sections were relevant to</p> <p>22 that?</p> <p>23 A. Those sections are pretty</p> <p>24 straightforward. This is a case -- or at</p>	<p>1 A. I don't know if that's a</p> <p>2 portion of the CSA or not. Again, I'm not a</p> <p>3 legal scholar, so this documentation is a</p> <p>4 little bit foreign to me.</p> <p>5 I point you to Page 3 of my</p> <p>6 report where I rely on this, and I say that</p> <p>7 this -- this law was requiring that</p> <p>8 distributors, quote/unquote, provide</p> <p>9 effective controls and procedures to guard</p> <p>10 against theft and diversion of controlled</p> <p>11 substances.</p> <p>12 My only point here is to say</p> <p>13 that there appears to be -- I'm not a lawyer,</p> <p>14 but there appears to be law about what</p> <p>15 distributors should be doing in terms of</p> <p>16 effective control and procedures to prevent</p> <p>17 diversion, not just of opioids but of</p> <p>18 controlled substances.</p> <p>19 Q. These other two documents, the</p> <p>20 third one, do you know what that is?</p> <p>21 A. So this looks like -- I'm just</p> <p>22 going to read it here, and then I'll describe</p> <p>23 my understanding. The Second Supplemental</p> <p>24 Objectives (sic) and Answers to Plaintiffs'</p>
<p style="text-align: center;">Page 163</p> <p>1 least my assignment was to look at whether or</p> <p>2 not Rite Aid as a distributor -- or one of</p> <p>3 the portions of my assignment was to look at</p> <p>4 whether Rite Aid as a distributor had an</p> <p>5 effective program for anti-diversion, one</p> <p>6 component of which would be a suspicious</p> <p>7 ordering monitoring program. The language in</p> <p>8 the CSA simply states that that is something</p> <p>9 that registrants should do.</p> <p>10 So the portion of my report</p> <p>11 that relies to it is only this point right</p> <p>12 here, which is to say there's a regulatory</p> <p>13 policy that organizations should be doing</p> <p>14 this.</p> <p>15 In my particular assignment, I</p> <p>16 was asked to evaluate how was Rite Aid doing</p> <p>17 it in this regard, along with other things in</p> <p>18 the assignment.</p> <p>19 Q. Okay. How about the second</p> <p>20 document listed in Other Court Documents, do</p> <p>21 you see that?</p> <p>22 A. I do.</p> <p>23 Q. Okay. Do you know what that</p> <p>24 is?</p>	<p style="text-align: center;">Page 165</p> <p>1 First Set of Interrogatories. My -- again,</p> <p>2 I'm not a legal scholar. My understanding of</p> <p>3 this document, the way I relied on it is it</p> <p>4 provides a summary as well as answers by</p> <p>5 counsel representing Rite Aid which includes</p> <p>6 direct material from -- I'm going to use the</p> <p>7 word fact experts, not knowing better words,</p> <p>8 from Rite Aid to describe various things that</p> <p>9 it had in place.</p> <p>10 So, for instance, in my own</p> <p>11 report, primarily in Section 4 of the report,</p> <p>12 I refer to specific Rite Aid employees who</p> <p>13 describe what are the processes that were in</p> <p>14 place. And a lot of that information is in</p> <p>15 this Second Supplemental Objections and</p> <p>16 Answers, for example, an auto-replenishment</p> <p>17 system, thresholds for distributing opioids,</p> <p>18 if you exceed it then you don't get the</p> <p>19 opioids, the system of putting opioids and</p> <p>20 other controlled substances in locked cages,</p> <p>21 etcetera.</p> <p>22 Q. How about the last item, do you</p> <p>23 know what that is?</p> <p>24 A. This one I don't recall.</p>

<p>1 (Whereupon, Jena Exhibit 2 Number 8 was marked for 3 identification.)</p> <p>4 BY MR. PIFKO:</p> <p>5 Q. Handing you what's marked as 6 Exhibit 8.</p> <p>7 A. Thanks.</p> <p>8 Q. Take a moment to review that, 9 and let me know when you're done.</p> <p>10 A. I reviewed it.</p> <p>11 Q. All right. Do you know what 12 that is?</p> <p>13 A. This is my CV.</p> <p>14 Q. Is this complete and accurate?</p> <p>15 A. Yes, it is.</p> <p>16 Q. Is it accurate as of today's 17 date?</p> <p>18 A. Yes, it is.</p> <p>19 Q. Is there any other work that 20 you have that you're engaged in that you need 21 to add to it?</p> <p>22 A. No.</p> <p>23 Q. Okay. We request that if you 24 do other updates to your CV, please provide</p>	<p>Page 166</p> <p>1 Q. Take a moment to review 2 Exhibit 9. Let me know when you're done.</p> <p>3 A. I'm done.</p> <p>4 Q. Exhibit 9 is another document 5 that was provided to me yesterday. Can you 6 tell me what Exhibit 9 is?</p> <p>7 A. Sure. Exhibit 9, Page 1 says 8 "Dr. Anupam Bapu Jena Professional Fees" 9 received.</p> <p>10 So these hours and amount paid 11 reflect what we went through earlier with 12 respect to the invoices. This is the direct 13 payments that I received from Analysis Group 14 for the National Prescription Opioid 15 Litigation with Rite Aid for my professional 16 fees.</p> <p>17 Q. The second page, do you know 18 what that reflects?</p> <p>19 A. Yes. The second page refers to 20 something called attribution, so this is all 21 of the billings from Analysis Group to -- for 22 Rite Aid work that's exclusive of my 23 professional billing, that's not included 24 here, that's separate billing. So this is</p> <p>Page 167</p> <p>1 to counsel an updated copy, okay?</p> <p>2 MS. MCENROE: Objection. We 3 will take that request under 4 advisement and supplement our 5 disclosures as obligated under the 6 rules from time to time.</p> <p>7 BY MR. PIFKO:</p> <p>8 Q. Do you have different versions 9 of your CV for different types of work?</p> <p>10 A. No.</p> <p>11 Q. Like some people have one -- 12 maybe like if you were seeking another 13 academic position, maybe you'd have one 14 version, versus if you're doing consulting 15 work you have another version.</p> <p>16 A. No. This is my only CV.</p> <p>17 Q. Okay.</p> <p>18 (Whereupon, Jena Exhibit 19 Number 9 was marked for 20 identification.)</p> <p>21 BY MR. PIFKO:</p> <p>22 Q. Handing you what's marked as 23 Exhibit 9.</p> <p>24 A. Thank you.</p>
	<p>Page 169</p> <p>1 the work of the various names that you saw on 2 the invoices that we talked about earlier.</p> <p>3 This is the billings to Rite Aid from 4 Analysis Group.</p> <p>5 Q. Do you know what all these 6 columns represent?</p> <p>7 A. Yes, I do.</p> <p>8 Q. Okay. What does the "AG 9 Eligible Prof Fees" column represents?</p> <p>10 A. So I believe that stands for 11 Analysis Group eligible professional fees. 12 So these would be the fees representing the 13 hours worked and the hourly rate of all of 14 the people that you saw on those invoices, 15 excluding me.</p> <p>16 Q. Okay. So that -- that was 17 going to be one of my questions.</p> <p>18 So that doesn't include the 19 numbers that are on Page 1 of Exhibit 9?</p> <p>20 A. That's correct. Those are 21 separate.</p> <p>22 Q. And then this only goes through 23 April, 2019, correct?</p> <p>24 A. That is correct.</p>

Page 170	Page 172
<p>1 Q. So if we look back at 2 Exhibit 3, we can see that -- go to the last 3 bundle of Exhibit 3, which is dated May 21, 4 2019. Let me know when you're there. 5 A. Yes, I see that. 6 Q. Okay. The third page in, we 7 can see that there's another [REDACTED] 8 [REDACTED] 9 A. Yes, I see that. 10 Q. Okay. So that would be in 11 addition to the [REDACTED] ? 12 MS. MCENROE: Objection to 13 form. 14 A. I believe so. You know, I 15 don't get involved in Analysis Group's 16 invoices, so I'm not an expert on those 17 particular issues. I can speak in detail 18 about my own professional services. 19 BY MR. PIFKO: 20 Q. Do you know anything about the 21 number of hours or dollar amounts billed by 22 Analysis Group in May? 23 A. I do not know what they billed 24 in May.</p>	<p>1 you provided all those materials to counsel? 2 A. Yep. Yes. So all documents 3 that I've reviewed since the date of my 4 report, which is no other documents. 5 Itemization of hours spent, 6 compensation paid, including all invoices, 7 all of the invoices that I've submitted to 8 Analysis Group, which is how I submit my 9 invoices, have been submitted. 10 And the CV that you just 11 presented me is the most current CV, and it's 12 my only CV. 13 Q. Your rate is currently 875? 14 A. My rate is currently \$875. 15 Q. How did you come to that 16 number? 17 A. It's reflective of the various 18 competing demands that I have on my time and 19 in my expertise as an MD and PhD in economics 20 and the type of work that I do. 21 Q. Did you develop that number on 22 your own, or did Analysis Group work with you 23 to select that number? 24 A. I developed that number on my</p>
<p style="text-align: center;">Page 171</p> <p>1 Q. How about in June leading up to 2 the deposition? 3 A. In the last four days, no, I 4 don't know. 5 (Whereupon, Jena Exhibit 6 Number 10 was marked for 7 identification.) 8 BY MR. PIFKO: 9 Q. Handing you what's marked as 10 Exhibit 10. Take a minute to review that, 11 and let me know when you're done. 12 (Witness reviewing document.) 13 A. Okay. I reviewed it. 14 Q. Okay. Have you seen this 15 before? 16 A. I saw this just before I came 17 into this room around 11:00 a.m. 18 Q. Okay. If you look to the last 19 page of Exhibit 10, there's some categories 20 of materials. 21 Do you see there? 22 A. The last page, yes, I see three 23 bullet points. 24 Q. Looking closely at those, have</p>	<p style="text-align: center;">Page 173</p> <p>1 own just understanding of what typical 2 consulting rates are for academics who do 3 consulting work. 4 Q. The -- some of the invoices 5 reflect that your time earlier was \$800 an 6 hour? 7 A. That is correct. 8 Q. You -- when did you increase it 9 to 875? 10 A. I suspect at the calendar year. 11 Q. Okay. 12 A. 2019, around that time. 13 Q. And what was the reason for the 14 increase? 15 A. Mostly just competing demands 16 on my time. 17 Q. Is there anything, to your 18 knowledge, inaccurate in your report? 19 A. No. 20 Q. We talked about testimony. 21 Have you ever -- aside from the -- like a 22 lawsuit, have you ever testified before a 23 government body? 24 A. I have never testified before a</p>

1 government body, no. 2 Q. Have you ever testified before 3 a grand jury proceeding? 4 A. No. 5 Q. Have you ever provided 6 testimony to the FDA? 7 A. Not to the FDA, no. 8 Q. Maybe less formal than 9 testimony, any statements or anything like 10 that? 11 A. No, no written statements to 12 the FDA. 13 Q. How about oral? 14 A. No oral statements, no. 15 Q. Okay. Have you ever done any 16 advertising for your expert work? 17 A. Advertising, no. 18 Q. How about any advertising for 19 consulting work? 20 A. No. 21 Q. When you were interacting with 22 counsel on this matter, did they provide you 23 with any assumptions to consider in 24 connection with your opinion?	Page 174 1 MR. PIFKO: We can go off the 2 record. I think I'm almost done here. 3 MS. MCENROE: Take a little 4 break. 5 THE VIDEOGRAPHER: The time is 6 2:44 p.m. We're off the record. 7 (Whereupon, a recess was 8 taken.) 9 THE VIDEOGRAPHER: The time is 10 2:49 p.m. We're on the record. 11 BY MR. PIFKO: 12 Q. Just one other question. 13 Do you understand yourself to 14 be only retained for the current bellwether 15 case track, or all opioid cases for Rite Aid? 16 MS. MCENROE: Objection to 17 form. 18 A. My understanding is I've been 19 retained for this particular case. 20 BY MR. PIFKO: 21 Q. Okay. Just the Cuyahoga and 22 Summit County cases? 23 A. Yes. 24 MR. PIFKO: Okay. So subject
1 A. No. 2 Q. Did they provide you with any 3 facts? 4 A. Can you clarify? What do you 5 mean by "facts"? 6 Q. Did they communicate anything 7 to you that they told you was a fact that you 8 should be aware of in connection with the 9 case? 10 A. The only facts that I rely on 11 in my report are the ones that my team 12 identified from the record in the matter. 13 Q. Okay. How about any data, did 14 counsel provide you with any data that you 15 used in forming your opinions? 16 A. No. The only -- the data that 17 we used is the ARCOS data. 18 Q. Were there any other databases 19 that your -- you or your team examined in 20 forming your report beside the ARCOS data? 21 A. No, just the ARCOS data. I 22 mean, I rely on publicly available documents 23 and studies, but those aren't databases, 24 those are studies.	Page 175 1 to any recross I may have based on 2 questions from other people, I don't 3 have any other further questions at 4 this time. 5 MS. MCENROE: I have just a 6 very few brief questions. 7 EXAMINATION 8 BY MS. MCENROE: 9 Q. Dr. Jena, nice to see you. As 10 you know, my name is Elisa McEnroe, counsel 11 for Rite Aid. 12 You testified just a minute ago 13 regarding the data that was considered in the 14 forming of your opinions. 15 Do you remember those lines of 16 questioning? 17 A. Yes. 18 Q. And you referred exclusively to 19 ARCOS data. Do you have any additions or 20 corrections to that response? 21 A. Yeah, I should be more clear. 22 I used the ARCOS data for the analysis of 23 Dr. McCann's methodology, suspicious order or 24 flag methodology, and I used Rite Aid

Page 178	Page 180
<p>1 distribution data for the falsification test 2 that we spoke about earlier looking at 3 levothyroxine, metoprolol succinate, and the 4 other falsification drugs.</p> <p>5 Q. As is reflected in Appendix E 6 of your report that we were looking at 7 earlier?</p> <p>8 A. That is correct.</p> <p>9 Q. And a little bit earlier this 10 afternoon you were discussing certain of 11 plaintiffs' experts who you know 12 professionally.</p> <p>13 Do you remember that?</p> <p>14 A. Yes.</p> <p>15 Q. And you referred to certain of 16 them and their being economists.</p> <p>17 Do you remember that?</p> <p>18 A. Yes.</p> <p>19 Q. Are you adopting any of their 20 opinions in this case?</p> <p>21 A. No, I'm not.</p> <p>22 MS. MCENROE: I have no further 23 questions.</p> <p>24 MR. PIFKO: All right. I don't</p>	<p>1 COMMONWEALTH OF MASSACHUSETTS) 2 SUFFOLK, SS.) 3 I, MAUREEN O'CONNOR POLLARD, RDR, 4 RSA, and Notary Public in and for the 5 Commonwealth of Massachusetts, do certify 6 that on the 6th day of June, 2019, at 11:09 7 o'clock, the person above-named was duly 8 sworn to testify to the truth of their 9 knowledge, and examined, and such examination 10 reduced to typewriting under my direction, 11 and is a true record of the testimony given 12 by the witness. I further certify that I am 13 neither attorney, related or employed by any 14 of the parties to this action, and that I am 15 not a relative or employee of any attorney 16 employed by the parties hereto, or 17 financially interested in the action.</p> <p>18 In witness whereof, I have 19 hereunto set my hand this 6th day of June, 20 2019.</p> <p>21 _____</p> <p>22 MAUREEN O'CONNOR POLLARD, NOTARY PUBLIC 23 CSR #149108</p> <p>24</p>
Page 179	Page 181
<p>1 have anything else.</p> <p>2 MS. MCENROE: Anybody else?</p> <p>3 MR. GEISE: No questions.</p> <p>4 MS. MCENROE: On the phone?</p> <p>5 Great, then that concludes</p> <p>6 Dr. Jena's deposition. Thank you.</p> <p>7 THE VIDEOGRAPHER: The time is 8 2:51 p.m. This deposition has 9 concluded, and we are off the record.</p> <p>10 (Whereupon, the deposition was 11 concluded.)</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>1 INSTRUCTIONS TO WITNESS</p> <p>2</p> <p>3 Please read your deposition over 4 carefully and make any necessary corrections.</p> <p>5 You should state the reason in the 6 appropriate space on the errata sheet for any 7 corrections that are made.</p> <p>8 After doing so, please sign the errata 9 sheet and date it. It will be attached to 10 your deposition.</p> <p>11 It is imperative that you return the 12 original errata sheet to the depoing 13 attorney within thirty (30) days of receipt 14 of the deposition transcript by you. If you 15 fail to do so, the deposition transcript may 16 be deemed to be accurate and may be used in 17 court.</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>

<p>1 ----- 2 E R R A T A 3 PAGE LINE CHANGE 4 _____ 5 REASON: _____ 6 _____ 7 REASON: _____ 8 _____ 9 REASON: _____ 10 _____ 11 REASON: _____ 12 _____ 13 REASON: _____ 14 _____ 15 REASON: _____ 16 _____ 17 REASON: _____ 18 _____ 19 REASON: _____ 20 _____ 21 REASON: _____ 22 _____ 23 _____ 24 _____</p>	<p>1 LAWYER'S NOTES 2 PAGE LINE 3 _____ 4 _____ 5 _____ 6 _____ 7 _____ 8 _____ 9 _____ 10 _____ 11 _____ 12 _____ 13 _____ 14 _____ 15 _____ 16 _____ 17 _____ 18 _____ 19 _____ 20 _____ 21 _____ 22 _____ 23 _____ 24 _____</p>
<p>10 Page 183 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> <p>1 WITNESS NAME DATE 11 12 13 14 15 16 17 Subscribed and sworn 18 To before me this 19 _____ day of _____, 20 _____. 20 21 My commission expires: _____ 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 259 260 261 262 263 264 265 266 267 268 269 269 270 271 272 273 274 275 276 277 278 279 279 280 281 282 283 284 285 286 287 288 289 289 290 291 292 293 294 295 296 297 298 299 299 300 301 302 303 304 305 306 307 308 309 309 310 311 312 313 314 315 316 317 318 319 319 320 321 322 323 324 325 326 327 328 329 329 330 331 332 333 334 335 336 337 338 339 339 340 341 342 343 344 345 346 347 348 349 349 350 351 352 353 354 355 356 357 358 359 359 360 361 362 363 364 365 366 367 368 369 369 370 371 372 373 374 375 376 377 378 379 379 380 381 382 383 384 385 386 387 388 389 389 390 391 392 393 394 395 396 397 398 399 399 400 401 402 403 404 405 406 407 408 409 409 410 411 412 413 414 415 416 417 418 419 419 420 421 422 423 424 425 426 427 428 429 429 430 431 432 433 434 435 436 437 438 439 439 440 441 442 443 444 445 446 447 448 449 449 450 451 452 453 454 455 456 457 458 459 459 460 461 462 463 464 465 466 467 468 469 469 470 471 472 473 474 475 476 477 478 479 479 480 481 482 483 484 485 486 487 488 489 489 490 491 492 493 494 495 496 497 498 499 499 500 501 502 503 504 505 506 507 508 509 509 510 511 512 513 514 515 516 517 518 519 519 520 521 522 523 524 525 526 527 528 529 529 530 531 532 533 534 535 536 537 538 539 539 540 541 542 543 544 545 546 547 548 549 549 550 551 552 553 554 555 556 557 558 559 559 560 561 562 563 564 565 566 567 568 569 569 570 571 572 573 574 575 576 577 578 579 579 580 581 582 583 584 585 586 587 588 589 589 590 591 592 593 594 595 596 597 598 598 599 599 600 601 602 603 604 605 606 607 608 609 609 610 611 612 613 614 615 616 617 618 619 619 620 621 622 623 624 625 626 627 628 629 629 630 631 632 633 634 635 636 637 638 639 639 640 641 642 643 644 645 646 647 648 649 649 650 651 652 653 654 655 656 657 658 659 659 660 661 662 663 664 665 666 667 668 669 669 670 671 672 673 674 675 676 677 678 679 679 680 681 682 683 684 685 686 687 688 689 689 690 691 692 693 694 695 696 697 698 698 699 699 700 701 702 703 704 705 706 707 708 709 709 710 711 712 713 714 715 716 717 718 719 719 720 721 722 723 724 725 726 727 728 729 729 730 731 732 733 734 735 736 737 738 739 739 740 741 742 743 744 745 746 747 748 749 749 750 751 752 753 754 755 756 757 758 759 759 760 761 762 763 764 765 766 767 768 769 769 770 771 772 773 774 775 776 777 778 779 779 780 781 782 783 784 785 786 787 788 789 789 790 791 792 793 794 795 796 797 798 798 799 799 800 801 802 803 804 805 806 807 808 809 809 810 811 812 813 814 815 816 817 818 819 819 820 821 822 823 824 825 826 827 828 829 829 830 831 832 833 834 835 836 837 838 839 839 840 841 842 843 844 845 846 847 848 849 849 850 851 852 853 854 855 856 857 858 859 859 860 861 862 863 864 865 866 867 868 869 869 870 871 872 873 874 875 876 877 878 879 879 880 881 882 883 884 885 886 887 888 889 889 890 891 892 893 894 895 896 897 898 898 899 899 900 901 902 903 904 905 906 907 908 909 909 910 911 912 913 914 915 916 917 918 919 919 920 921 922 923 924 925 926 927 928 929 929 930 931 932 933 934 935 936 937 938 939 939 940 941 942 943 944 945 946 947 948 949 949 950 951 952 953 954 955 956 957 958 959 959 960 961 962 963 964 965 966 967 968 969 969 970 971 972 973 974 975 976 977 978 979 979 980 981 982 983 984 985 986 987 988 989 989 990 991 992 993 994 995 996 997 998 998 999 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1098 1099 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1198 1199 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1298 1299 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1398 1399 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1498 1499 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1598 1599 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1698 1699 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1798 1799 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1898 1899 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1919 1920 1921 1922 1923 1924 1925</p>	